Synthesis and evaluation of lysophosphatidylserine analogues as inducers of mast cell degranulation. Potent activities of lysophosphatidylthreonine and its 2-deoxy derivative

Article abstract of DOI:10.1021/jm900598m

In response to various exogenous stimuli, mast cells (MCs) release a wide variety of inflammatory mediators stored in their cytoplasmic granules and this release initiates subsequent allergic reactions. Lysophosphatidylserine (lysoPS) has been known as an exogenous inducer to potentiate histamine release from MCs, though even at submicromolar concentrations. In this study, through SAR studies on lysoPS against MC degranulation, we identified lysoPT, a threonine-containing lysophospholipid and its 2-deoxy derivative as novel strong agonists. LysoPT and its 2-deoxy derivative induced histamine release from MCs both in vitro and in vivo at a concentration less than one-tenth that of lysoPS. Notably, lysoPT did not activate a recently proposed lysoPS receptor on MCs, GPR34, demonstrating the presence of another undefined receptor reactive to both lysoPS and lysoPT that is involved in MC degranulation. Thus, the present strong agonists, lysoPT and its 2-deoxy derivative, will be useful tools to understand the mechanisms of lysoPS-induced activation of degranulation of MCs. 2009 American Chemical Society.

Full text of DOI:10.1021/jm900598m

J. Med. Chem. 2009, 52, 5837–5863 5837
DOI: 10.1021/jm900598m
Synthesis and Evaluation of Lysophosphatidylserine Analogues as Inducers of Mast Cell Degranulation.
Potent Activities of Lysophosphatidylthreonine and Its 2-Deoxy Derivative
Masazumi Iwashita,†,3 Kumiko Makide,‡, ,O,3 Taro Nonomura,† Yoshimasa Misumi,† Yuko Otani,† Mayuko Ishida,§
Ryo Taguchi,§,^ Masafumi Tsujimoto, Junken Aoki,*,‡,#,O Hiroyuki Arai,‡,^ and Tomohiko Ohwada*,†
†Laboratory of Organic and Medicinal Chemistry and ‡Department of Health Chemistry and Graduate School of Pharmaceutical Sciences, The
University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan, §Department of Metabolome, Faculty of Medicine, The University of
Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan, Laboratory of Cellular Biochemistry, RIKEN, 2-1, Hirosawa, Wako-shi, Saitama,
351-0198, Japan, ^CREST and #PRESTO, Japan Science and Technology Agency, Kawaguchi, Saitama 332-8613, Japan. 3 M. Iwashita and
K. Makide contributed equally to this work. O Present address: Department of Molecular and Cellular Biochemistry, Graduate School of
Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan.
Received May 7, 2009
In response to various exogenous stimuli, mast cells (MCs) release a wide variety of inflammatory
mediators stored in their cytoplasmic granules and this release initiates subsequent allergic reactions.
Lysophosphatidylserine (lysoPS) has been known as an exogenous inducer to potentiate histamine
release from MCs, though even at submicromolar concentrations. In this study, through SAR studies on
lysoPS against MC degranulation, we identified lysoPT, a threonine-containing lysophospholipid and
its 2-deoxy derivative as novel strong agonists. LysoPT and its 2-deoxy derivative induced histamine
release from MCs both in vitro and in vivo at a concentration less than one-tenth that of lysoPS.
Notably, lysoPT did not activate a recently proposed lysoPS receptor on MCs, GPR34, demonstrating
the presence of another undefined receptor reactive to both lysoPS and lysoPT that is involved in MC
degranulation. Thus, the present strong agonists, lysoPT and its 2-deoxy derivative, will be useful tools
to understand the mechanisms of lysoPS-induced activation of degranulation of MCs.
Introduction
rodents by antigens or concanavalin A (ConA), a cross-
linker of FcεRI, lysoPS significantly enhances the degranu-
lation responses.3,4 LysoPS also induces the degranulation
of peritoneal MCs when injected i.v. in rodents even in the
absence of FcεRI-cross-linking. Enhancement of MC de-
granulation, however, can be observed at a rather high
dose, i.e., a submicromolar concentration of lysoPS. In
addition, the action is highly specific to lysoPS, and all
other lysophospholipids examined, including the analogue
containing the unnatural D-serine moiety, were ineffective
inducers of MC degranulation.7
Mast cells (MCsa) play an important role in immediate-type
allergic reactions by releasing chemical mediators such as hista-
mine and serotonin from their secretary granules in response to
an antigen.1,2 Histamine release from MCs is a key process in
allergic diseases such as pollinosis, urticaria, atopic dermatitis,
and asthma. Indeed, more than half of the population suffers
from such diseases, especially in developed countries, and the
number of patients is increasing annually. Identification of
molecules that modulate MC degranulation would be helpful
in providing tools to investigate the molecular mechanisms of
allergic reactions as well as candidate antiallergy drugs.
Exogenous lysophosphatidylserine (lysoPS; sn-1-acyl-
lysoPS) has been known to strongly enhance the degranula-
tion of rodent MCs.3 Upon cross-linking of IgE-bound FcεRI
(a high-affinity receptors for IgE) on peritoneal MCs from
Thus, a specific receptor for lysoPS has been postulated to
be present on MCs.5,6,11 It is likely that lysoPS is produced
from phosphatidylserine (PS), which is exposed on the cell
surface of apoptotic or activated cells, by the action of
PS-specific phospholipase A1 (PS-PLA1).8-10 Recently, Sugo
et al. reported that an orphan G-protein-coupled receptor,
called GPR34, was activated specifically by lysoPS.11 Because
GPR34 was expressed in MC, they proposed that GPR34
was a strong candidate for the putative lysoPS receptor
on MCs.11
*To whom correspondence should be addressed. For J.A.: phone,
þ81-22-795-6860; fax, þ81-22-795-6859; E-mail, jaoki@mol.f.u-tokyo.
ac.jp, jaoki@mail.pharm.tohoku.ac.jp. For T.O.: phone, þ81-3-5841-
4730; fax, þ81-3-5841-4735; E-mail, ohwada@mol.f.u-tokyo.ac.jp.
a Abbreviations: MCs, mast cells; lysoPS, lysophosphatidylserine;
lysoPT, lysophosphatidylthreonine; PS, phosphatidylserine; ConA,
concanavalin A; FcεRI, a high-affinity receptors for IgE; anti-DNP-
AS, antidinitrophenol-ascaris antibody; BMMCs, bone marrow-de-
rived mast cells; LDH, lactate dehydrogenase; BSA, bovine serum
albumin; RPMCs, rat peritoneal mast cells; MPMCs, mouse peritoneal
mast cells; Bn, benzyl; Z, benzyloxycarbonyl; DEAD, diethyl azodicar-
boxylate; CSA, camphorsufonic acid; MMTr, 4-methoxytrityl; DIPEA,
diisopropylethylamine; TBAI, tetrabutylammonium iodide; p-TSA,
p-toluenesulfonic acid; DMAP, N,N-dimethylaminopyridine; CAN,
cerium(IV) ammonium nitrate.
While the enhancement of the MC degranulation is highly
specific to lysoPS among other lysophospholipids,7 the effec-
tive concentration of lysoPS is rather high, so that it may
r
2009 American Chemical Society
Published on Web 09/10/2009
pubs.acs.org/jmc

5838 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Iwashita et al.
Figure 1. LysoPS analogues synthesized in this study.
Scheme 1. Synthesis of 1-4a
a (a) Stearoyl chloride, pyridine, CH2Cl2, rt, 1 d; (b) BnOH, Et3N, Et2O, 0 ꢀC, 2 h; (c) N-Z-L-Ser benzyl ester, 1H-tetrazole, CH2Cl2-THF, rt, 2 h;
(d) 23-26, 1H-tetrazole, CH2Cl2-THF, rt, 2 h, then TBHP, rt, 1 h; (e) Pd-C (10%), H2, MeOH-AcOH, rt, 1 d.
be possible to design higher-affinity agonistic ligands. Such
high-affinity ligands would be useful tools for mechanistic
studies of MC degranulation. In this study, we therefore
synthesized a number of lysoPS analogues and finally found
that simple replacement of the serine residue of lysoPS with
the threonine residue (i.e., threonine-containing lysophospho-
lipid (lysophosphatidylthreonine, lysoPT) and its 2-deoxy
derivative) resulted in a dramatic increase in potency for
inducing MC degranulation and in vivo hypothermic effects.
This in vivo hypothermic effect was not detected in MC-
deficient mice. This fact strongly supported the postulate that
these new derivatives also target MCs in vivo. We disclosed
here the structure-activity relationships of the chemical
inducers of MC degranulation. In addition, using the present
agonist, lysoPT, wedemonstrated thatGPR34 isnot activated
by lysoPT, suggesting a postulate that GPR34 is not the
common receptor involved in the MC degranulation.
Chemistry
We synthesized a variety of lysoPS analogues (1-22), including
lysoPS (5) itself (Figure 1; for details of the synthesis and char-
acterization of lysoPS analogues (1-22), see the Experimental
Section and Schemes 1-9). In designing these molecules, we
modified the glycerol part (1-8) (Schemes 1 and 2), the fatty acid
linkage (9and 10) (Scheme 3), added a methyl group at carbon and
hetero atoms of various positions of the serine moiety (methyl
scanning, 11-14) (Schemes 4 and 5), and conformationally con-
strained the serine moiety (15-17) (Scheme 6). Because the chain
length of the fatty acid moiety might affect the potency of lysoPS
analogues, a stearic acid (18:0) unit was principally used in this

Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5839
Scheme 2. Synthesis of 5-8a
a (a) p-Methoxyphenol, DEAD, PPh3, toluene, 70 ꢀC,2h;(b) CSA, MeOH, rt,1d;(c) MMTrCl, DIPEA, TBAI,CH2Cl2, rt, 2 h; (d) BnBr, NaH, TBAI, THF,
0ꢀC, 10min, tort, 1h;(e) MeI,NaH, THF, 0ꢀC 10 min to rt, 2 h; (f) CSA or p-TSA, MeOH-CH2Cl2 (3:1),30min;(g) 28, 1H-tetrazole, CH2Cl2-THF, rt, 2h, then
TBHP, rt, 1 h; (h) CAN, CH3CN-H2O (4:1), 0 ꢀC, 20 min; (i) stearoyl chloride, DMAP, CH2Cl2, 0 ꢀC to rt, 30 min; (j) Pd-C (10%), H2, MeOH-AcOH, rt, 1 d.
Scheme 3. Synthesis of 9 and 10a
a (a) Stearoyl chloride, pyridine, DMF, 50 ꢀC, 3 h; (b) MMTrCl, DIPEA, TBAI, THF, 50 ꢀC, 2 h; (c) BnBr, NaH, THF, 0 ꢀC, 10 min, to rt, 1 h; (d) MeI,
NaH, THF, 0 ꢀC 10 min to rt, 2 h; (e) CSA, MeOH-CH2Cl2 (3:1), 30 min; (f) 28, 1H-tetrazole, CH2Cl2-THF, rt, 2 h, then TBHP, rt, 1 h; (g) Pd-C (10%),
H2, MeOH-AcOH, rt, 1 d.
study unless otherwise mentioned. A phosphoramidite method was
used to construct the phosphate diester linkage in these analogues.
benzyloxybis(diisopropylamino)phosphine in the presence of
1H-tetrazole (B), followed by a second phosphorylation with a
protected glycerol.12 Subsequent in situ oxidation of the resul-
tant phosphite triester intermediate with tert-butyl hydroper-
oxide afforded the fully protected phosphate triester (C).
Selective oxidative deprotection of the terminal oxygen atom
of the glycerol moiety, followed by acylation with stearoyl
chloride (D), and complete deprotection furnished 11. We also
synthesized the corresponding deoxy derivative of lysoPT,
i.e., 2-deoxy-lysoPT (18 and 19), as illustrated in Scheme 7.
The synthesis of lysoPT (11) is shown in Scheme 4. The C,
N-terminally protected threonine (A) was phosphorylated with

5840 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Scheme 4. Synthesis of 11 and 12a
Iwashita et al.
a (a) Z-Cl, sat NaHCO3, THF, 0 ꢀC, 1 h; (b) BnBr, TBAI, THF, rt, 16 h; (c) 27, 1H-tetrazole, CH2Cl2-THF, rt, 2 h; (d) 43, 1H-tetrazole, CH2Cl2-THF,
rt, 2 h, then TBHP, rt, 1 h; (e) CAN, CH3CN-H2O (4:1), 0 ꢀC, 20 min; (f) stearoyl chloride, DMAP, CH2Cl2, 0 ꢀC to rt, 30 min; (g) Pd-C (10%), H2,
MeOH-AcOH, rt, 1 d.
Scheme 5. Synthesis of 13 and 14a
a (a) Z-Cl, saturated NaHCO3, THF, 0 ꢀC, 1 h; (b) BnBr, TBAI, THF, rt, 16 h; (c) 27, 1H-tetrazole, CH2Cl2-THF, rt, 2 h; (d) 43, 1H-tetrazole, CH2Cl2-
THF, rt, 2 h, then TBHP, rt, 1 h; (e) CAN, CH3CN-H2O (4:1), 0 ꢀC, 20 min; (f) stearoyl chloride, DMAP, CH2Cl2, 0 ꢀC to rt, 30 min; (g) Pd-C (10%), H2,
MeOH-AcOH, rt, 1 d.
The effect of the chain length of the fatty acid moiety of 11 was
also studied by synthesizing 20 and 21 with different chain
length (C12 and C16, respectively) (Scheme 8). To examine the
effect of the position of acyl chains, i.e., sn-1-acyl vs sn-2-acyl
analogue, we synthesized 22 as a sn-2-acyl-1-deoxy lysoPS
analogue (Scheme 9). We tested the potency of lysoPS analo-
gues to activate MCs both in vitro and in vivo. To evaluate the
histamine release from MCs in vitro, MCs isolated from the rat
or mouse peritoneal cavity were incubated with each analogue
in the presence of ConA, an FcεRI cross-linker. The potency of
an analogue was defined as the amount of histamine released as
a percent of the total amount of histamine contained in the cells.
Results and Discussions
In Vitro Histamine Release from Peritoneal Mast Cells. We
examined the effects of the synthetic compounds on the

Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5841
Scheme 6. Synthesis of 15-17a
a (a) Z-Cl, sat NaHCO3, THF, 0 ꢀC, 1 h; (b) BnBr, TBAI, THF, rt, 16 h; (c) 27, 1H-tetrazole, CH2Cl2-THF, rt, 2 h; (d) 43, 1H-tetrazole, CH2Cl2-THF,
rt, 2 h, then TBHP, rt, 1 h; (e) CAN, CH3CN-H2O (4:1), 0 ꢀC, 20 min; (f) stearoyl chloride, DMAP, CH2Cl2, 0 ꢀC to rt, 30 min; (g) Pd-C (10%), H2,
MeOH-AcOH, rt, 1 d.
Scheme 7. Synthesis of 18 and 19a
Scheme 8. Synthesis of 20 and 21a
a (a) CAN, CH3CN-H2O (4:1), 0 ꢀC, 20 min; (b) RCOCl (RdC11H23
or C15H31), DMAP, CH2Cl2, 0 ꢀC to rt, 30 min; (c) Pd-C (10%), H2,
MeOH-AcOH, rt, 1 d.
a (a) 24 (for 92) or 93 (for 94), 1H-tetrazole, CH2Cl2-THF, rt, 2 h, then
TBHP, rt, 1 h; (b) Pd-C (10%), H2, MeOH-AcOH, rt, 1 d.
were found to retain activity to induce histamine release from
rat peritoneal MCs (RPMCs).
For example, 7, a diastereoisomer bearing an sn-2-(S)-
hydroxyl group, sn-2-(R)- (6), and sn-2-(S)- (8) methyl ether
analogues showed activity at concentrations several fold
higher than 5 (Table 1 and Figure S1, Supporting In-
formation). The results show that, in contrast to the cases
of other lysophospholipids such as lysophosphatidic acid
(lysoPA)13 and their receptors, the sn-2 hydroxyl group of
activation of peritoneal MC degranulation (Table 1, Figure 2,
and Figure S1 (Supporting Information)). We first confirmed
that the synthetic lysoPS (18:0) (5), which has a (R)-hydroxyl
group at the sn-2 position, exhibited degranulation-inducing
activity (Figure 2a and 2b). We synthesized lysoPS analogues
(1-4 and 6-8), modified at the glycerol part, and some of them

5842 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Scheme 9. Synthesis of 22a
Iwashita et al.
Table 1. EC50 Values of LysoPS Analogues for Peritoneal Mast Cell
Degranulation
EC50
compd
rat, μM
mouse, μM
Modification of Glycerol Moiety
>10
1 (deoxy, n = 1)
nda
∼0.04
nd
2 (2-deoxy-lysoPS, n = 2)
3 (deoxy, n = 3)
4 (deoxy, n = 4)
5 (lysoPS, 2R-OH)
6 (2R-OMe)
∼0.5
∼5
>10
nd
∼0.4
∼2
∼0.1
nd
7 (2S-OH)
8 (2S-OMe)
∼1
∼0.07
nd
∼5
a (a) DMTrCl, DIPEA, TBAI, CH2Cl2, rt; (b)NaH, PMBCl, TBAI,
THF, 0-70 ꢀC; (c) PPTS, CH2Cl2-MeOH, rt; (d) 28, 1H-tetrazole,
CH2Cl2-THF; (e) TBHP, rt; (f) DDQ, CH2Cl2-phosphate buffer (1:1),
0 ꢀC, 1 h; (g) RCOCl (RdC17H35), DMAP, CH2Cl2, 0 ꢀC, 1 h; (h) H2,
Pd-C, MeOH, AcOH, rt.
Modification of Fatty Acid Linkage
9 (NH-amide)
10 (NMe-amide)
∼5
nd
nd
∼10
C-Methyl Scanning
11 (lysoPT (18:0))
12 (lysoPalloT)
∼0.04
∼2
∼0.01
∼0.2
lysoPS is not essential for recognition. This prompted us to
synthesize 2, a deoxy analogue of the sn-2-hydroxyl group,
i.e., 2-deoxy-lysoPS, because acylation of lysoPS at the
sn-2 hydroxyl group to regenerate PS is the major inactiva-
tion pathway of lysoPS on MCs.6 It is likely that the 2-deoxy
derivative shows superior stability in vivo and in vitro
because it is resistant to inactivation by acylation. As expec-
ted, 2 was found to show similar activity to 5, again showing
that sn-2 hydroxyl group of lysoPS is not essential for its
activity (Figure 2a,b and Table 1). We also synthesized sn-2-
acyl lysoPS analogue, i.e., sn-2-acyl-1-deoxy-lysoPS (22).
Unlike 2, 22 was found to be inert (data not shown). Thus
the position of the sn-1-acyl group is crucial in the deoxy
derivatives. This is in sharp contrast to the observation of the
similar magnitude of the activities of sn-1-acyl and sn-2-acyl
lysoPS on MC degranulation.8
Other analogues (1, 3, 4, 9, 10, and 13-17; Table 1 and
Figure 1), modified at the glycerol moiety, the fatty acid
linkage, and by conformational constriction of the serine
moiety, had significantly diminished activity (Figure S1,
Supporting Information), indicating that the chain length
of the glycerol moiety, the ester linkage at the sn-1 position,
and the L-serine residue of lysoPS are important for activa-
tion of the putative lysoPS receptor.
Heteroatom-Methyl Scanning
13 (lysoPS-CO2Me)
14 (lysoPS-NHMe)
>10
>10
nd
nd
Conformation-Constrained Serine
15
16
17
>10
>10
>10
nd
nd
nd
LysoPT Analogues and Others
18 (2-deoxy-lysoPT (18:0))
19 (2-deoxy-lysoPT (16:0))
19-D (2-deoxy-lysoP(D-T) (16:0))
20 (lyosPT (12:0))
∼0.1
∼0.007
nd
nd
∼0.06
>10
∼0.15
∼0.04
∼0.05
∼0.02
nd
21 (lysoPT (16:0))
22 (1-deoxy-lysoPS)
a nd = not determined.
>10
results suggest that the stereochemistry of the threonine residue
is critically recognized by the putative lysoPS receptor. We
confirmed that both 5 and 11 enhanced antigen-induced hista-
mine release from IgE-sensitized RPMCs (Figure 2f). In this
case, 11 induced histamine release at a concentration about
10-fold lower than that of 5.
In the course of methyl scanning of the serine moiety, we
found that the synthetic lysoPS analogue that showed the
strongest activity in stimulating histamine release was 11,
lysophosphatidylthreonine (lysoPT), which has an addi-
tional methyl group at the β-carbon atom of serine in the
R configuration (L-threonine). Compound 11 induced hista-
mine release from isolated MCs both from rats (Figure 2c)
and mice (Figure 2d) at concentrations ∼10-fold lower than
that of 5.
Because 2 was found to retain activity, we synthesized the
corresponding deoxy derivatives of lysoPT, i.e., 2-deoxy-
lysoPT (18 (stearate) and 19 (palmitate)), as illustrated in
Scheme 7. Compounds 18 and 19 showed almost equal
activity to 11 in inducing histamine release (Figure 2c,d,e).
These results are consistent with the idea that the sn-2
hydroxyl group of lysoPS is not essential.
To examine the effect of acyl chain length in the fatty acid
moiety of lysoPT, we synthesized lysoPT analogues derived
from lauric acid (12:0) (20) or palmitic acid (16:0) (21)
(Scheme 8). Compound 21 was more potent than 11 in
inducing histamine release in vitro, but the activity of 20
was almost equal to that of 11 (Figure 3a,b and Table 1),
indicating that hydrocarbon chain length has a significant
effect. Compounds 11, 18, and 21 were also effective in vivo;
they induced rapid elevation of plasma histamine level after
i.v. injection of these lysoPT analogues (Figure 3c). The rank
order of potencies of lysoPS analogues in MC degranulation
was 21 (lysoPT (16:0)) . 11 (lysoPT (18:0)) = 20 (lysoPT
(12:0) g 19 (2-deoxy-lysoPT (16:0)) > 18 (2-deoxy-lysoPT
(18:0))>5 (lysoPS)>2 (2-deoxy-lysoPS) . 12 (lysoPalloT).
Lysophospholipids may have a nonspecific cell mem-
brane-perturbing, i.e., cytotoxic, effect. Thus, we tested
whether or not lysoPT is cytotoxic to MCs by measuring
release of a cytoplasmic enzyme, lactate dehydrogenase
(LDH). We found that 11, as well as 5, did not induce
any detectable LDH release even at a high concentration
(50 μM), whereas lysophosphatidylcholine (lysoPC), used as
A diastereomer of lysoPT with respect to the stereochemistry
of the methyl group, the (S)-methyl (i.e., allo-threonine) analo-
gue 12, lysoPalloT (Figure 1), was found to be a poor agonist
(Figure 2c,d). 2-Deoxy-lysoPT containing the D-threonine
moiety (19-D) was ineffective, as expected (Figure 2e). These

Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5843
Figure 2. Effect of lysoPS analogues on mast cell degranulation. (a-e) Effect of lysoPS analogues on ConA-induced histamine release from
rodent peritoneal mast cells in vitro. Isolated rat (a,c,e) or mouse (b,d) peritoneal mast cells were incubated for 15 min with each lysoPS
analogue at the indicated concentrations in the presence of ConA. (f) Effect of lysoPS analogues on antigen-induced histamine release from
IgE-sensitized RPMCs in vitro. IgE (anti-DNP-As)-sensitized RPMCs were stimulated with 100 ng/mL DNP-As in the presence of lysoPS
(5) or lysoPT (11). Histamine release was determined by fluorometric assay and is expressed as a percent of the total cell histamine. Values are
the means ( SE of three independent experiments.
a cytotoxic positive control, induced significant LDH release
(Figure S2, Supporting Information). These data exclude the
possibility that lysoPT induces MC degranulation as a result
of nonspecific membrane perturbation.
(Figure 4e) and 18 (data not shown), like 5,7 induced no
hypothermic response in W/Wv mice, indicating that both 11
and 18 act on MCs.
LysoPT Does Not Activate LysoPS Receptor GPR34. To
know possible mechanism of action of lysoPS and lysoPT on
MCs, we further examined whether 11 activates GPR34, a
recently proposed G-protein-coupled receptor for lysoPS.11
We confirmed that 5 inhibited forskolin-induced cyclic AMP
production (Figure 5a), induced a transient increase in an
intracellular Ca2þ concentration ([Ca2þ]i) (Figure 5b), and
activated MAP kinase (Figure 5c) in GPR34-expressing
CHO-K1 stable transformant (CHO-GPR34) cells. These
changes were not observed in mock-transfected CHO-K1
cells. On the other hand, 11 unexpectedly did not induce
any of the above three responses in CHO-GPR34 cells
(Figure 5a-c). The data clearly show that 11 does not
activate GPR34. GPR34 was reported to be highly expressed
in bone marrow-derived MCs (BMMCs) in mice. Because
BMMCs do not respond to lysoPS,11 we examined if GPR34
is expressed by lysoPS-reactive peritoneal MCs. As shown in
Figure 5d, it was revealed that GPR34 was not detected in
In Vivo Hypothermic Effects of LysoPT and Its 2-Deoxy
Derivative. To test the activity of 11 in vivo, we examined
whether lysoPT has a hypothermic effect like that induced by
lysoPS.14 When 11 was injected into mice and rats, it caused
transient decreases of body temperature at concentra-
tions 20- and 50-fold lower, respectively, than those of 5
(Figure 4a,b,c). As expected, from in vitro experiments
(Figure 2), lysoPalloT (12) and 2-deoxy-lysoPT containing
the D-threonine moiety (19-D) were found to be ineffective
in inducing the hypothermic effect (data not shown). By
contrast, 18 also showed potent hypothermic effects in vivo
(Figure 4d). As already mentioned, 11, 18, and 21 were
effective in vivo to induce rapid elevation of plasma hist-
amine level (Figure 3c).
To confirm that lysoPT really targets MCs in vivo, the
hypothermic effects of 11 and 18 were examined in MC-
deficient WBB6F1-W/Wv (W/Wv) mice. Compounds 11

5844 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Iwashita et al.
Our present data also suggest that MCs have a mechanism
for degranulation that distinguishes the precise and overall
structures of 5 and 11. As shown in Figure S3 of the
Supporting Information, RPMCs that were preincubated
with 11 and then washed with buffer containing 0.01% BSA
(bovine serum albumin) (fatty acid free) still released hist-
amine in response to ConA. In contrast, histamine release
from lysoPT-treated MCs was significantly suppressed when
the cells were washed with buffer containing 0.5% BSA.
Because a high concentration (0.5%) of fatty acid-free BSA
is known to extract lysophospholipids from the cell surface,
but not from intracellular pools,6 the result supports the idea
that lysoPT binds to its target molecule, probably the
putative lysoPT receptor, on the MC surface. Thus, together
with several preceding studies, it is strongly suggested that
MCs have a target of lysoPT. It remains possible that lysoPS
and lysoPT have different individual targets whose activa-
tion would induce MC degranulation. However, our experi-
ment using MC-deficient mice confirmed that MCs are the
target cells for both lipids, lysoPS and lysoPT (Figure 4e).
From the present and past results of the structure-activity
relationships, similar modification of 5 and 11 resulted in
similar changes in MC degranulation; for example, deoxy-
compounds 2 and 18 were both active (Figure 2a-d).
Further, both D-serine and D-threonine analogues showed
weakened responses (Figure 2e),7 suggesting that the two
lipids target the same molecule on MCs, that is, the putative
lysoPS/lysoPT receptor. More biological studies on the
mechanisms on lysoPS-induced MC degranulation should
be carried out to examine these and other postulations by
using the present strong agonists such as 11, 18, and 19.
Conclusion
In the present study, we found strong agonists, 11, 18, and
19 as inducers of MC degranulation. The latter 2-deoxy
derivarives (18 and 19) have an apparent advantage for in
vivo/vitro studies because one of the major inactivation
processes, i.e., acylation of lysoPS at the sn-2 hydroxyl group
to regenerate PS, is excluded.
Figure 3. Effect of changing the acyl chain length of lysoPT. (a,b)
Rat (a) or mouse (b) peritoneal mast cells were incubated for 15 min
with lysoPT containing lauric acid (12:0) (20), palmitic acid (16:0)
(21), or stearic acid (18:0) (11) at the indicated concentrations in the
presence of 100 μg/mL of ConA. Histamine release is expressed as a
percent of the total cell histamine. Values are the means ( SE of
three independent experiments. (c) Plasma histamine level of after
i.v. injection of lysoPT analogues. C57BL/6 mice were injected
intravenously with lysoPT analogues at the indicated dose. Plasma
was taken 2 min after the injection, and histamine levels were
determined with an EIA system. Values are the means ( SE of
three independent experiments.
We synthesized a series of novel lysoPS analogues. Most of
our synthetic lysoPS analogues with modified serine head
groups were inactive, suggesting that the putative lysoPS
receptor appears to specifically recognize the structure of
lysoPS. Chang et al. previously showed that modification of
L-serine part, i.e., D-serine-containing lysoPS (D-lysoPS), dra-
matically reduced the histamine release-inducing activity.7
A similar significant loss of activity was observed in the case
of 2-deoxy-lysoPT containing the D-threonine moiety, 19-D.
We also found that lysoPS analogues with modifications in
glycerol part (1, 3, and 4) and in acyl chain linkage (9 and 10)
were found to be inactive (Figure S1, Supporting Infor-
mation). Thus, the putative lysoPS receptor appears to specifi-
cally recognize the structure of lysoPS. However, it is inter-
esting to find that the hydroxyl residue at the sn-2 position of
lysoPS and lysoPT glycerol backbone did not affect the
histamine release-inducing activity, indicating that this resi-
due is not involved in the recognition by the putative lysoPS/
lysoPT receptor. The precise mechanism of lysoPS-induced
MC degranulation, including the nature of the putative
lysoPS/lysoPT receptor, remains to be identified. However,
because the receptor is involved in IgE-antigen induced MC
degranulation, it is a potential target for antiallergic drugs.
Our discovery of the high affinity ligand, lysoPT and 2-deoxy
peritoneal MCs from both mice (Figure 5d) and rats (data
not shown), while it was highly expressed by mouse BMMCs
as reported previously.11 All these data indicate that GPR34
is not the receptor involved in lysoPS-induced degranulation
in peritoneal MCs. Our results suggest that GPR34 is
different from the putative lysoPS receptor responsible for
lysoPS-induced degranulation, indicating the presence of
novel receptor(s) for lysoPS/lysoPT involved in MC degra-
nulation. So far, the physiological role of GPR34 receptor is
not clear. Interestingly, GPR34 was highly expressed in
BMMCs, which are regarded as premature MCs. As lysoPS
does not stimulate the degranulation of BMMCs, GPR34
may have other function in BMMCs. While the present and
past biological data are contradictory, and more biological
study will be awaited, the present result demonstrated use-
fulness of our new agonist (lysoPT) in the relevant research
field.

Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5845
Figure 4. Hypothermic effect of lysoPS analogues. C57BL/6 mice (a,b,d) or Wistar rats (c) were injected intravenously with lysoPS (5), lysoPT
(11), or 2-deoxy-lysoPT (18) at the indicated dosage and rectal temperature was monitored every 5 or 10 min. (e) LysoPT does not induce
hypothermia in mast cell-deficient (W/Wv) mice. C57BL/6 mice or W/Wv mice were injected i.v. with 10 μg of lysoPT and rectal temperature
was monitored. Values are the means ( SE of three independent experiments.
lysoPT, definitely provide a molecularbasisforunderstanding
of the mechanisms of activation of degranulation of MCs.
resultant solution was dried by coevaporation with toluene.
Under argon atmosphere, to a solution of the resultant mixture
in CH2Cl2, a solution of 1H-tetrazole (1 equiv) in THF was
added at room temperature. In a few minutes, white solids were
precipitated. The whole was stirred for 2 h at room temperature,
and the reaction was quenched with the addition of saturated
aqueous NaHCO3, and the whole was diluted with EtOAc. The
organic layer was washed with saturated aqueous NaHCO3 and
brine and was dried over Na2SO4. The solvent was evaporated,
and the resultant residue was chromatographed to yield a pure
product. In the purification with column chromatography,
Et3N deactivated silica gel was used, that is, eluents containing
3% (v/v) Et3N.
Experimental Section
Synthesis of LysoPS Analogues. General Methods. All re-
agents were purchased from Sigma-Aldrich Chemical Co.,
Tokyo Kasei Kogyo Co., Wako Pure Chemical Industries,
and Kanto Kagaku Co., Inc. LysoPS (porcine brain) for bioas-
say was purchased from Avanti Polar Lipids. Silica gel for
column chromatography was purchased from Kanto Kagaku
Co., Inc. 1H and 13C 31P NMR spectra were recorded on a
1
Bruker Avance 400 spectrometer. Chemical shifts of H- and
13C-NMR spectra were shown in terms of parts per million
(ppm), relative to those of chloroform (7.24 ppm for 1H NMR
spectra, and 77.00 ppm for 13C NMR spectra). Chemical shifts
of 31P signals were reported in terms of parts per million (ppm),
relative to that of phosphoric acid in water (85% w/w, as 0.00
ppm). Mass spectral data was recorded on a Bruker microTOF-
05 (ESI-TOF) in the positive and negative ion detection modes.
General Procedure for Synthesis of Monodiisopropylamino Phos-
phoramidite (General Procedure A). Bis(diisopropylamino)-
phosphite 27 (1.0 equiv) was dissolved in CH2Cl2. To this
solution, the corresponding alcohol (1 equiv) was added. The
General Procedure for Synthesis of Phosphate Triester Using
Phosphoramidite Method and Oxidation (General Procedure B).
Phosphoramidite (e.g., 28) and an alcohol were dissolved in
CH2Cl2. The resultant solution was dried by coevaporation with
toluene. Under argon atmosphere, to a solution of the resultant
mixture in CH2Cl2, a solution of 1H-tetrazole in THF was added
at room temperature. In a few minutes, white solids were
precipitated. The reaction mixture was stirred for 2 h at rt,
and then a solution of t-butyl hydroperoxide (TBHP) in decane
was added, and the whole was stirred for 1 h at rt. The obtained
organic layer was washed with saturated aqueous NaHCO3 and

5846 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Iwashita et al.
Figure 5. LysoPT does not activate GPR34. (a) Effect of lysoPT (11) on cAMP accumulation in forskolin-stimulated CHO-K1 cells stably
expressing mouse GPR34 (CHO-GPR34). The cells were incubated with various concentrations of lysoPS (5) or lysoPT (11), and the forskolin-
induced cAMP accumulation was measured by EIA assay. The cAMP level in the absence of ligand is defined as 100%. (b) Effect of lysoPT (11)
on intracellular calcium mobilization ([Ca2þ]i) in CHO-GPR34 cells. Fura-2-loaded CHO-GPR34 cells were stimulated with 2 μM lysoPS (5) or
lysoPT (11), and [Ca2þ]i was determined fluorometrically using CAF-110. (c) Effect of lysoPT (11) on ERK activation in CHO-GPR34 cells.
Serum-starved CHO-GPR34 cells were stimulated with either lysoPS (5) or lysoPT (11), and phosphorylated (pERK) and total ERK (tERK)
were detected by Western blot analysis. Results from mock-transfected CHO cells are shown as a negative control. (d) GPR34 mRNA
expression in mast cells. Total RNAs were prepared from mouse peritoneal mast cells (MPMCs) or mouse bone marrow-derived mast cells
(BMMCs), and the amount of GPR34 RNA were analyzed by quantitative real-time PCR. The copy numbers for GPR34 were normalized by
those of GAPDH.
brine and was dried over Na2SO4. The solvent was evaporated,
and the resultant residue was chromatographed to yield a pure
product.
alcohol, carboxylic acid, and N,N-dimethylaminopyridine
(DMAP) were dissolved in CH2Cl2. To the solution was added
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
(EDCI) at 0 ꢀC and then stirred for 24 h at room temperature.
After quenching of the reaction with 3 M aqueous HCl, the
organic layer was washed with 3 M aqueous HCl and brine, and
the whole was dried over Na2SO4. The solvent was evaporated,
and the resultant residue was chromatographed to yield a pure
product.
General Procedure for Synthesis of N-benzyloxycarbonyl (Z)
Amino Acid (General Procedure E). An amino acid was dissolved
in a mixture of saturated NaHCO3 and THF, and the whole was
cooled to 0 ꢀC. To this solution, a solution of benzyl chloro-
formate in THF was added at 0 ꢀC and the whole was stirred for
1 h at 0 ꢀC. After quenching the reaction with 3 M aqueous HCl
General Procedure for Synthesis of Fatty Acid Ester from
Fatty Acid Chloride (General Procedure C). An alcohol and a
base (e.g., pyridine) were dissolved in CH2Cl2. To this solution,
a solution of an acid chloride in CH2Cl2 was added dropwise
at 0 ꢀC, and the reaction mixture was stirred for 24 h. After
quenching of the reaction with 3 M aqueous HCl, the obtained
organic layer was washed with 3 M aqueous HCl and brine, and
the whole was dried over Na2SO4. The solvent was evaporated,
and the resultant residue was chromatographed to yield a pure
product.
General Procedure for Synthesis of Fatty Acid Ester from
Fatty Acid using EDCI and DMAP (General Procedure D). An

Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5847
at 0 ꢀC, the organic layer was washed with 3 M aqueous HCl and
brine and dried over Na2SO4. The solvent was evaporated, and
the resultant residue was chromatographed to yield a pure
product.
General Procedure for Synthesis of N-Z Amino Acid Benzyl
Ester (General Procedure F). A Z-amino acid, tetrabutylam-
monium iodide (TBAI), and Et3N were dissolved in THF. To
this solution was added a solution of benzyl bromide at room
temperature. The reaction mixture was stirred for 16 h. The
whole was washed with 3 M aqueous HCl, saturated NaHCO3,
and brine, and the whole was dried over Na2SO4. The solvent
was evaporated, and the resultant residue was chromatographed
to yield a pure product.
General Procedure for 4-Methoxytrityl (MMTr) or 4,4-Di-
methyltrityl (DMTr) Protection of Alcohol (General Procedure G).
To a solution of an alcohol and TBAI in CH2Cl2, diisopro-
pylethylamine (DIPEA) was added. To this solution 4-methoxy-
triphenylmethyl chloride (MMTrCl) (or 4,40-dimethoxytri-
phenylmethyl chloride (DMTrCl)) was added at rt, and the
whole was stirred for 2 h. After quenching the reaction with 3 M
aqueous HCl, saturated NaHCO3, and brine, and the whole was
dried over Na2SO4. The solvent was evaporated, and the
resultant residue was chromatographed to yield a pure product.
General Procedure for Benzyl Etherification of Alcohol
(General Procedure H). Under argon atmosphere to a solution
of an alcohol and TBAI in THF, NaH (55% in mineral oil) was
added at 0 ꢀC and the whole was stirred for 10 min. Then, benzyl
bromide was added to the solution at 0 ꢀC, and the whole was
stirred for 1 h at room temperature. After quenching the
reaction with ice water, the obtained organic layer was diluted
with EtOAc, and the whole was washed with brine and dried
over Na2SO4. The solvent was evaporated, and the resultant
residue was chromatographed to yield a pure product.
General Procedure for Methyl Etherification of Alcohol and
N-Methylation of Amide (General Procedure I). Under argon
atmosphere, to a solution of an alcohol in THF, NaH (55% in
mineral oil) was added at 0 ꢀC. The whole was stirred for 10 min,
and then methyl iodide was added to this solution at 0 ꢀC, and
the whole was stirred for 2 h at rt. After quenching the reaction
with ice water, the organic layer was diluted with EtOAc, and
the whole was washed with brine and dried over Na2SO4. The
solvent was evaporated, and the resultant residue was chro-
matographed to yield a pure product.
General Procedure for Deprotection of MMTr Group (General
Procedure J). An MMTr-protected alcohol was dissolved in
CH2Cl2-MeOH (1:3). To this solution a catalytic amount of
p-toluenesulfonic acid (p-TSA) or camphorsulfonic acid (CSA)
was added, and the whole was stirred for 30 min at room
temperature. After quenching the reaction with Et3N, the whole
was washed with brine and dried over Na2SO4. The solvent was
evaporated, and the resultant residue was chromatographed to
yield a pure product.
General Procedure for Deprotection of 4-Methoxyphenyl
(PMP) Group and Synthesis of Stearate (General Procedure K).
A PMP-protected alcohol was dissolved in CH3CN-H2O,
and the whole was cooled to 0 ꢀC. To this solution, CAN was
added and the whole was stirred for 20 min. After quenching the
reaction with saturated aqueous NaHCO3, the obtained organic
layer was diluted with EtOAc, washed with saturated aqueous
NaHCO3, brine, and was dried over Na2SO4. The solvent was
evaporated, and the resultant residue was chromatographed to
yield a pure product. The product was dissolved in CH2Cl2, and
DMAP was added and the whole was cooled to 0 ꢀC. To this
solution a solution of stearoyl chloride in CH2Cl2 was added
dropwise at 0 ꢀC, and the whole was stirred for 30 min. The
solvent was evaporated, and the resultant residue was chroma-
tographed to yield a pure product.
Pd-C (10%) for 1 day. The catalyst was filtered off through
celite and the organic layer was evaporated and the resultant
residue was chromatographed to yield a pure product.
Synthesis of 2-Deoxy-lysoPS Analogues 1-4(Scheme 1). Synthesis
of Compound 1. Compound 27.
To a suspension of bis(diisopropylaminochlorophosphine)
(15.0 g, 56.2 mmol) in dry Et2O (300 mL), a solution of benzyl
alcohol (6.21 mL, 60.0 mmol) and Et3N (9.10 mL, 65.0 mmol) in
Et2O was added dropwise at 0 ꢀC. The reaction mixture was
stirred for 2 h at 0 ꢀC and then the formed white solids were
removed, the solvent of the filtrate was evaporated, and the
residue was chromatographed (Et3N/hexane 3:97) to yield
27 (17.89 g, 94%, colorless oil). 1H NMR (CD2Cl2): δ 7.31
(5H, m), 4,63 (2H, d, J=3.2 Hz), 3.57 (4H, m), 1.18 (24H, m).
13C NMR (CDCl3): δ 140.96, 140.86, 127.09, 127.07, 66.51,
66.28, 44.80, 44.67, 24.65, 24.57, 24.00, 23.94. HRMS (ESI,
[M þ H]þ): Calcd for C19H36N2OP: 339.2565. Found: 339.2584.
Compound 28.
Following the general procedure A, 27 (2.61 g, 7.70 mmol),
N-Z-serine benzyl ester (2.31 g, 7.00 mmol), 1H-tetrazole (490.4 mg,
7.00 mmol), CH2Cl2 (40 mL), and THF (15 mL) were used. The
crude mixture was chromatographed (EtOAc/hexane/Et3N20:80:3)
to yield 28 (3.51 g, 6.19 mmol, 88%, colorless oil), a mixture of trans/
cis isomers with respect to the benzyloxycarbonylamino group.
1H NMR (CD2Cl2): δ 7.30 (15H, m), 5.86 (1/2H, d, J=4.2 Hz),
5.65 (1/2H, d, J=4.2Hz),5.16(2H,m),5.08(2H,m),4.72-4.50 (3H,
m), 4.15 (1H, m), 3.90 (1H, m), 3.58 (2H, m), 1.14 (12H, m). HRMS
(ESI, [M þ Na]þ): Calcd for C31H39N2NaO6P: 589.2443. Found:
589.2466.
Compound 23.
Following the general procedure C, stearoyl chloride (1.68 g,
21.0 mmol), ethylene glycol (1.29 g, 5.55 mmol), CH2Cl2
(50 mL), and pyridine (1 mL) were used. The crude mixture
was chromatographed (EtOAc/hexane 1:2 to 3:2) to yield 23
1
(1.27 g, 3.87 mmol, 70%, white solid); mp 56.0-56.5 ꢀC. H
NMR (CDCl3): δ 4.10 (2H, t, J=6.4 Hz), 3.68 (2H, t, J=6.4 Hz),
2.29 (2H, t, J=7.8 Hz), 1.55 (2H, m), 1.25 (28H, m), 0.88 (3H, t,
J=6.8 Hz). HRMS (ESI, [M þ Na]þ): Calcd for C20H40NaO3:
351.2875. Found: 351.2871.
Compound 29.
General Procedure for Simultaneous Deprotection of Benzyl and
Benzyloxycarbonyl (Z) Protective Group (General Procedure L).
A substrate was hydrogenated in MeOH-AcOH (4:1) over
Following the general procedure B, 23 (82.4 mg, 0.251 mmol), 28
(170.0 mg, 0.298 mmol), 1H-tetrazole (52.6 mg, 0.750 mmol),
TBHP (0.125 mL, 0.75 mmol), CH2Cl2 (1 mL), and THF (1.5 mL)

5848 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Iwashita et al.
were used. The crude mixture was chromatographed (EtOAc/
hexane 2:3) to yield 29 (140.8 mg, 0.168 mmol, 67%, colorless oil),
a mixture of trans/cis isomers with respect to the benzyloxycarbo-
nylamino group. 1HNMR(CDCl3):δ7.31 (15H, m), 5.82 (1/2H, d,
J=4.2 Hz), 5.76 (1/2H, d, J=4.2 Hz), 5.17 (2H, m), 5.09 (2H, m),
4.96 (2H, m), 4.58 (1H, m), 4.41 (1H, m), 4.27 (1H, m), 4.04 (2H,
m), 2.25 (2H, t, J=7 Hz), 1.55 (2H, m), 1.23(28H, m), 0.86 (3H, t,
J=6.8 Hz).13C NMR (CDCl3): δ 173.43, 168.66, 155.78, 135.97,
135.26, 135.20, 134.86, 128.71, 128.58, 128.56, 128.48, 128.45,
128.41, 128.34, 128.26, 128.16, 128.11, 128.04, 127.94, 69.72,
69.67, 67.68, 67.31, 67.13, 65.74, 65.69, 62.49, 62.42, 54.41, 33.89,
31.85, 29.62, 29.58, 29.54, 29.40, 29.29, 29.20, 29.04, 24.70, 22.62,
12.06. 31P NMR (CDCl3): δ -0.67. HRMS (ESI, [M þ Na]þ):
Calcd for C45H64NNaO10P: 832.4166. Found: 832.4184.
Compound 1.
34.13, 31.85, 29.6, 29.63, 29.59, 29.45, 29.3, 29.25, 29.13,
24.86, 22.66, 14.10. 31PNMR(CDCl3):δ-0.42, -0.44. HRMS (ESI,
[M þ Na]þ): Calcd for C46H66NNaO10P: 846.4322. Found: 846.4351.
Compound 2 (2-Deoxy-lysoPS).
Following the general procedure L, 30 (50.0 mg, 0.0606 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1
to 8:1:1), and the product was washed with MeOH to yield 2
(18.2 mg, 0.0357 mmol, 59%, white powder). 1H NMR (CDCl3/
CD3COOD 4:1): δ 4.43 (1H, m), 4.33 (1H, m), 4.23 (1H, m), 4.06
(2H, m), 3.90 (2H, m), 2.20 (2H, t, J=6.4 Hz), 1.48(4H, m), 1.13
(28H, m), 0.74 (3H, t, J=6.8 Hz). HRMS (ESI, [M - H]-):
Calcd for C24H47NO8P: 508.3039. Found: 508.3014. Anal.
3
Calcd for C24H48NO8P þ /5CF3CO2H: C, 52.36; H, 8.47; N,
2.42. Found: C, 52.35; H, 8.44; N, 2.39. mp 150.5-151.0 ꢀC.
Synthesis of Compound 3. Compound 25.
Following the general procedure L, 29 (34.0 mg, 0.0406 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL, 4:1) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to 8:1:1),
and the product was washed with methanol to yield 1(15.4 mg, 0.0294
mmol, 72%, white powder). 1H NMR (CDCl3/CD3CO2D 4:1):
δ 4.34 (2H, m), 4.15 (3H, m), 4.00 (2H, m), 2.25 (2H, m), 1.53 (4H,
m), 1.17 (28H, m), 0.79 (3H, t, J=6.6 Hz). HRMS (ESI, [M - H]-):
Calcd for C23H451NO8P: 494.2883. Found: 494.2880. Anal. Calcd for
C23H46NO8P þ /3CF3CO2H: C, 53.27; H, 8.75; N, 2.62. Found: C,
53.22; H, 8.54; N, 2.55. mp 155.5-156.0 ꢀC.
Following the general procedure C, stearoyl chloride (3.02 g,
10.0 mmol), 1,4-butane diol (3.63 g, 40.0 mmol), CH2Cl2 (50 mL),
and pyridine (2 mL) were used. The crude mixture was chromato-
graphed (EtOAc/hexane 1:3) to yield 25 (2.45 g, 6.87 mmol, 69%,
white solid). 1HNMR(CDCl3):δ4.10 (2H, t, J=6.4 Hz), 3.68 (2H, t,
J=6.4 Hz), 2.29 (2H, t, J=7.8 Hz), 1.72 (2H, m), 1.48 (4H, m), 1.25
(28H, m), 0.88 (3H, t, J=6.8 Hz). HRMS (ESI, [M þ Na]þ): Calcd
for C22H44NaO3: 379.3188. Found: 379.3183. mp 40.5-41.0 ꢀC.
Compound 31.
Synthesis of Compound 2 (2-Deoxy-lysoPS). Compound 24.
Following the general procedure C, stearoyl chloride (612.7 mg,
2.20 mmol), 1,3-propane diol (617.4 mg, 8.11 mmol), CH2Cl2
(3 mL), and pyridine (0.2 mL) were used. The crude mixture was
chromatographed (EtOAc/hexane 1:3) to yield 24 (453.8 mg,
1.44 mmol, 66%, white solid). 1H NMR (CDCl3): δ 4.10 (2H, t,
J=6.4 Hz), 3.68 (2H, t, J=6.4 Hz), 2.29 (2H, t, J=7.8 Hz), 1.72
(2H, m), 1.60 (1H, m), 1.53 (2H, m), 1.25 (28H, m), 0.88 (3H, t, J=
6.8 Hz). HRMS (ESI, [M þ Na]þ): Calcd for C21H42NaO3:
365.3032. Found: 365.3038. mp 51.5-52.0 ꢀC.
Following the general procedure B, 25 (177.9 mg, 0.500 mmol), 28
(304.4 mg, 0.550 mmol), 1H-tetrazole (62.9 mg, 0.900 mmol), TBHP
(0.2 mL, 1.20 mmol), CH2Cl2 (2 mL), and THF (1.8 mL) were used.
The crude mixture was chromatographed (EtOAc/hexane 1:3 to1:2)
Compound 30.
1
to yield 31 (339.4 mg, 0.405 mmol, 81%, colorless oil). H NMR
(CDCl3):δ7.32 (15H, m), 5.85 (1/2H, d, J=4.2 Hz), 5.78 (1/2H, d, J=
4.2 Hz), 5.18 (2H, m), 5.11 (2H, m), 4.98 (2H, m), 4.58 (1H, m), 4.41
(1H,m),4.28(1H,m), 4.01(2H, m),3.92(2H,m),2.26(2H,t,J=7.5
Hz), 1.61 (4H, m), 1.56 (2H, m), 1.25 (28H, m), 0.88 (3H, t, J=6.4
Hz). 13C NMR (CDCl3): δ 173.81, 168.74, 155.79, 136.00, 135.47,
135.44, 134.89, 128.68, 128.59, 128.48, 128.25, 128.18, 128.07,
127.97, 77.20, 69.63, 69.57, 67.69, 67.15, 63.38, 54.44, 34.22, 31.87,
29.65, 29.61, 29.56, 29.43, 29.31, 29.23, 29.12, 24.90, 24.73, 22.64,
14.08. 31P NMR (CDCl3): δ -0.40, -0.46. HRMS (ESI, [M þ
Na]þ): Calcd for C47H68NNaO10P: 860.4479. Found: 860.4467.
Compound 3.
Following the general procedure B, 24 (128.7 mg, 0.360 mmol), 28
(240.7 mg, 0.420 mmol), 1H-tetrazole (62.9 mg, 0.900 mmol),
TBHP (0.2 mL, 1.20 mmol), CH2Cl2 (2 mL), and THF (1.8 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 1:3 to 1:2) to yield 30 (240.3 mg, 0.292 mmol, 81%, colorless
oil). A mixture of trans/cis isomers with respect to the benzyloxy-
carbonylamino group was present. 1H NMR (CDCl3): δ 7.26
(15H, m), 5.86 (1/2H, d, J=4.2 Hz), 5.78 (1/2H, d, J=4.2 Hz), 5.18
(2H, m), 5.11 (2H, m), 4.98 (2H, m), 4.60 (1H, m), 4.44 (1H, m),
4.28 (1H, m), 4.07 (2H, m), 3.98 (2H, m), 2.25 (2H, t, J=7.0 Hz),
1.87 (2H, m), 1.55 (2H, m), 1.25(28H, m), 0.88 (3H, t, J=6.4 Hz).
13C NMR (CDCl3): δ 173.68, 168.74, 155.81, 136.01, 135.44,
135.38, 134.90, 128.72, 128.62, 128.50, 128.29, 128.20, 128.09,
127.98, 77.21, 69.66, 69.61, 67.71, 67.17, 64.74, 60.00, 54.44,
Following the general procedure L, 31 (61.6 mg, 0.0736 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude

Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5849
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1
to 8:1:1), and the product was washed with MeOH to yield 3
(25.2 mg, 0.0481 mmol, 65%, white powder). 1H NMR (CDCl3/
CD3CO2D 4:1): δ 4.39 (1H, m), 4.29 (1H, m), 4.23 (1H, m),
3.94 (2H, m), 3.81 (2H, m), 2.16 (2H, t, J=7.6 Hz), 1.55 (4H, m),
1.45 (2H, m), 1.13 (28H, m), 0.73 (3H, t, J=8.0 Hz). HRMS
(ESI, [M - H]-) Calcd for C25H49NO8P: 522.3196. Found:
522.3192. Anal. Calcd for C25H50NO8P þ 1/3CF3CO2H: C,
55.47; H, 9.17; N, 2.54. Found: C, 55.76; H, 9.03; N, 2.56. mp
143.5-144.0 ꢀC.
Synthesis of Lyso-PS Derivatives 5-8 (Scheme 2). Synthesis
of Compound 5. Compound 33.
(R)-(-)-2,2-Dimethyl-1,3-dioxolane-4-methanol (5.00 g, 37.8
mmol), triphenylphosphine (12.90 g, 49.2 mmol), and p-methoxy-
phenol (14.09 g, 113.5 mmol) was dissolved in toluene. To the
solution DEAD (2.2 M in toluene, 22.4 mL, 49.3 mmol) was added
and warmed to 70 ꢀC and stirred for 2 h. The reaction mixture was
evaporated and chromatographed (Et2O/hexane 1:15) to yield 33
Synthesis of Compound 4. Compound 26.
1
(8.487 g, 35.62 mmol, 94%, colorless oil). H NMR (CDCl3):
δ 6.82 (4H, m), 4.44 (1H, m), 4.13 (1H, m), 3.99 (1H, m), 3.88 (1H,
m), 3.86 (1H, m), 3.74 (3H, s), 1.43 (3H, s), 1.38 (3H, s). 13C NMR
(CDCl3): δd 153.96, 152.62, 121.78, 115.37, 114.48, 114.28, 109.53,
73.99, 69.40, 66.73, 55.53, 55.42, 26.67, 25.25. HRMS (ESI, [M þ
Na]þ): Calcd for C13H18NaO4: 261.1103. Found: 261.1109.
Compound 35.
Following the general procedure C, stearoyl chloride (3.05 g,
10.1 mmol), 1,4-pentane diol (4.23 g, 40.0 mmol), CH2Cl2
(50 mL), and pyridine (2 mL) were used. The crude mixture
was chromatographed (EtOAc/hexane 1:3) to yield 26 (2.84 g,
1.44 mmol, 76%, white solid). 1H NMR (CDCl3): δ 4.08 (2H, t,
J=6.6 Hz), 3.66 (2H, t, J=6.4 Hz), 2.29 (2H, t, J=7.6 Hz), 1.64
(3H, m), 1.48 (2H, m), 1.43 (4H, m), 1.25 (28H, m), 0.88 (3H, t,
J=6.8 Hz). HRMS (ESI, [M þ Na]þ): Calcd for C23H46NaO3
393.3345. Found: 393.3339. mp 39.5-40.0 ꢀC.
Compound 32.
To a solution of 33 (1.00 g, 4.20 mmol) in MeOH (150 mL),
Amberlyst-15 (655.2 mg) was added, and the whole was stirred
for 1 d at room temperature. Amberlyst-15 was filtered off, the
solvent of the filtrate was evaporated, and the residue was
chromatographed (EtOAc/hexane 2:1 to 4:1) to yield 35 (1.13
g, 3.80 mmol, 90%, colorless oil). 1H NMR (CDCl3): δ 6.82 (4H,
m), 4.07 (1H, m), 3.99 (2H, m), 3.81 (1H, m), 3.75 (3H, s), 3.72
(1H, m), 2.05 (2H, bs). 13C NMR (CDCl3): δ 154.00, 152.48,
115.44, 114.57, 70.55, 69.68, 63.63, 55.58. HRMS (ESI, [M þ
Na]þ): Calcd for C10H14NaO4: 221.0790. Found: 221.0773. mp
74.5-75.0 ꢀC.
Following the general procedure B, 26 (238.0 mg, 0.360 mmol),
28 (133.3 mg, 0.360 mmol), 1H-tetrazole (52.6 mg, 0.750 mmol),
TBHP (0.1 mL, 0.600 mmol), CH2Cl2 (2 mL), and THF (1.5 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 1:3 to 1:2) to yield 32 (254.0 mg, 0.298 mmol, 83%,
colorless oil). 1H NMR (CDCl3): δ 7.27 (15H, m), 5.85 (1/2H, d,
J=4.2 Hz), 5.78 (1/2H, d, J=4.2 Hz), 5.18 (2H, m), 5.10 (2H, m),
4.98 (2H, m), 4.58 (1H, m), 4.41 (1H, m), 4.28 (1H, m), 4.01 (2H,
m), 3.90 (2H, m), 2.27 (2H, t, J=7.5 Hz), 1.56 (8H, m), 1.25(28H,
m), 0.87 (3H, t, J=6.8 Hz). 13C NMR (CDCl3): δ 173.90, 168.77,
155.79, 136.01, 135.54, 135.48, 134.91, 128.67, 128.60, 128.50,
128.24, 128.20, 128.09, 127.96, 69.57, 69.51, 67.95, 67.70, 67.10,
63.85, 54.53, 34.18, 31.89, 29.66, 29.63, 29.58, 29.45, 29.33,
29.25, 29.14, 28.07, 24.94, 22.66, 21.82, 14.08. 31P NMR
(CDCl3): δ -0.29, -0.34. HRMS (ESI, [M þ Na]þ): Calcd for
C48H70NNaO11P: 874.4636. Found: 874.4629.
Compound 37.
Following the general procedure G, 35 (695.6 mg, 3.51 mmol),
TBAI (394.2 mg, 1.07 mmol), DIPEA (1.36 g, 1.83 mL, 10.5
mmol), 4-methoxy tritylchloride (1.18 g, 3.83 mmol), and
CH2Cl2 (30 mL) were used. The crude mixture was chromato-
graphed (EtOAc/hexane 1:4 to 1:2) to yield 37 (1.57 g, 3.20
1
Compound 4.
mmol, 91%, yellow oil). H NMR (CDCl3): δ 7.41 (6H, m),
7.30-7.18 (8H, m), 6.80 (4H, m), 4.09 (1H, m), 3.99 (2H, m),
3.77 (3H, s), 3.75 (3H, s), 3.30 (2H, m). 13C NMR (CDCl3):
δ 158.50, 153.92, 152.60, 147.07, 144.18, 144.16, 135.28, 130.28,
129.14, 128.28, 127.78, 127.03, 126.88, 115.45, 114.58, 114.53,
113.07, 86.41, 70.33, 69.79, 69.72, 69.47, 64.10, 63.54, 55.60,
55.09. HRMS (ESI, [M þ Na]þ): Calcd for C30H30NaO5:
493.1991. Found: 493.2000.
Compound 39.
Following the general procedure L, 32 (62.8 mg, 0.0737 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1), and the product was washed with MeOH to yield 4 (27.1
mg, 0.0504 mmol, 68%, white powder). 1H NMR (CDCl3/
CD3CO2D 4:1): δ 4.36 (1H, m), 4.23 (1H, m), 3.89 (2H, m),
3.74 (2H, m), 2.13 (2H, t, J=7.4 Hz), 1.55 (6H, m), 1.45 (3H, m),
1.08 (28H, m), 0.68 (3H, t, J=8.0 Hz). HRMS (ESI, [M - H]-):
Calcd for C26H51NO8P: 536.3352. Found: 536.3341. Anal.
Following the general procedure H, 37 (1.39 g, 2.96 mmol),
TBAI (328.7 mg, 0.89 mmol), NaH (323.0 mg, 7.40 mmol),
benzyl bromide (760.4 mg, 4.45 mmol), and THF (30 mL) were
used. The crude mixture was chromatographed (EtOAc/hexane
1
Calcd for C26H52NO8P þ /3CF3CO2H: C, 52.71; H, 8.46; N,
2.23. Found: C, 52.38; H, 8.87; N, 2.40. mp 146.5-147.0 ꢀC.

5850 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Iwashita et al.
1:15 to 1:12) to yield 39 (1.48 g, 2.64 mmol, 89%, yellow oil). 1H
NMR (CDCl3): δ 7.42 (4H, m), 7.35-7.18 (11H, m), 6.78
(8H, m), 4.66 (2H, m), 4.05 (2H, m), 3.88 (1H, m), 3.76 (3H,
s), 3.74 (3H, s), 3.31 (2H, m). 13C NMR (CDCl3): δ 158.41,
153.74, 152.81, 144.36, 144.34, 138.38, 135.45, 130.28, 128.32,
128.21, 127.69, 127.46, 126.74, 115.43, 114.44, 112.96, 86.33,
72.18, 68.80, 63.02, 55.51, 55.00. HRMS (ESI, [M þ Na]þ):
Calcd for C37H36NaO5: 583.2460. Found: 583.2476.
Compound 43.
29.30, 29.22, 29.08, 24.79, 22.63, 14.07. 31P NMR (CDCl3): δ
-0.22, -0.24. HRMS (ESI, [M
C53H72NNaO11P: 952.4741. Found: 952.4744.
þ
Na]þ): Calcd for
Compound 5 (LysoPS).
Following the general procedure L, using 51 (30.0 mg, 0.0323
mmol), Pd-C (3.0 mg), and MeOH-AcOH (5 mL). The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to 7:2:1), and the product was washed with MeOH to yield
5 (9.2 mg, 0.0175 mmol, 58%, white solid). 1H NMR (CDCl3/
CD3CO2D 4:1): δ 4.85-4.34 (3H, m), 4.32-3.88 (5H, m), 2.23
(2H, m), 1.55(2H, m), 1.08 (28H, m), 0.76 (3H, t, J=7.0 Hz).
HRMS (ESI, [M - H]-) Calcd for C24H47NO9P: 524.2988.
Following the general procedure J, 39 (1.45 g, 2.64 mmol), CSA
(183.6 mg, 0.790 mmol), and CH2Cl2-MeOH (20 mL) were used.
The crude mixture was chromatographed (EtOAc/hexane 1:3)
to yield 43 (673.7 mg, 2.22 mmol, 84%, white solid). 1H NMR
(CDCl3): δ 7.34 (5H, m), 6.81 (4H, m), 4.72 (2H, m), 4.03 (2H,
4
Found: 524.2964. Anal. Calcd for C24H48NO9P þ /5CF3CO2H:
m), 3.87 (1H, m), 3.84 (1H, m), 3.75 (3H, s), 3.73 (1H, m). 13
C
C, 49.85; H, 7.97; N, 2.27. Found: C, 49.64; H, 8.04; N, 2.59. mp
160.0-160.5 ꢀC.
Synthesis of Compound 6. Compound 44.
NMR (CDCl3): δ 153.92, 152.45, 115.39, 114.52, 70.55, 69.58,
63.58, 55.51. HRMS (ESI, [M þ Na]þ): Calcd for C17H20NaO4:
311.1259. Found: 311.1252. mp 44.5-45.0 ꢀC.
Compound 47.
Following the general procedure J, 40 (1.30 g, 2.68 mmol),
p-toluenesulfonic acid (51.0 mg, 0.268 mmol), and CH2Cl2-
MeOH (30 mL) were used. The crude mixture was chromato-
graphed (EtOAc/hexane 1:2 to 1:1) to yield 44 (475.4 mg, 2.24
Following the general procedure B, 43 (151.7 mg, 0.500 mmol),
28 (337.2 mg, 0.610 mmol), 1H-tetrazole (105.7 mg, 1.51 mmol),
TBHP (0.42 mL, 2.52 mmol), CH2Cl2 (2 mL), and THF (3 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 3:7) to yield 47 (291.1 mg, 0.378 mmol, 76%, colorless
1
mmol, 84%, white solid). H NMR (CDCl3): δ 6.82 (4H, m),
4.03(2H, m), 3.83 (1H, m), 3.75 (3H, s), 3.71 (1H, m), 3.63 (1H,
m), 3.51 (3H, m), 1.76 (1H, bs). HRMS (ESI, [M þ Na]þ): Calcd
for C11H16NaO4: 235.0946. Found: 235.0951. mp 48.0-48.5 ꢀC.
Compound 48.
1
oil). H NMR (CDCl3): δ 7.26-7.30 (20H, m), 6.76 (4H, m),
5.88 (1H, m), 5.14 (2H, m), 5.06 (2H, m), 4.93 (2H, m), 4.63 (2H,
m), 4.57 (1H, m), 4.38 (1H, m), 4.23 (1H, m), 4.21(1H, m),
4.09 (1H, m), 3.90 (2H, m), 3.84 (1H, m), 3.73 (3H, s). HRMS
(ESI, [M þ Na]þ): Calcd for C42H44NNaO11P: 792.2550.
Found: 792.2550.
Compound 51.
Following the general procedure B, 44 (106.5 mg, 0.502 mmol),
28 (303.2 mg, 0.535 mmol), 1H-tetrazole (96.3 mg, 1.38 mmol),
TBHP (0.42 mL, 2.52 mmol), CH2Cl2 (2 mL), and THF (3 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 3:7) to yield 48 (267.5 mg, 0.386 mmol, 77%, colorless
1
oil). H NMR (CDCl3): δ 7.28-7.31 (15H, m), 6.76 (4H, m),
5.92 (1H, m), 5.15 (2H, m), 5.08 (2H, m), 4.97 (2H, m), 4.56
(1H, m), 4.41 (1H, m), 4.29 (1H, m), 4.19 (1H, m), 4.09 (1H, m),
3.88 (2H, m), 3.73 (3H, s), 3.62 (1H, m), 3.40 (3H, m). HRMS
(ESI, [M þ Na]þ): Calcd for C36H40NnaO11P: 716.2237. Found:
716.2237.
Following the general procedure K, 47 (154.0 mg, 0.200 mmol),
CAN (266.7 mg, 0.487 mmol), and CH3CN-H2O (2 mL) were
used. The crude mixture was chromatographed (EtOAc/hexane
1:2 to 3:2) to yield the alcohol (104.2 mg, 0.153 mmol, 77%,
brown oil). The resultant alcohol (104.2 mg, 0.153 mmol) was
acylated with stearoyl chloride (55.6 mg, 0.183 mmol) in CH2Cl2
(1.5 mL) in the presence of DMAP (56.0 mg, 0.458 mmol). The
crude mixture was chromatographed (EtOAc/hexane 1:3 to 2:3)
to yield 51 (112.2 mg, 0.121 mmol, 79%, colorless oil). 1H NMR
(CDCl3): δ 7.27 (20H, m), 5.86 (1H, m), 5.13 (2H, m), 5.08 (2H,
m), 4.95 (2H, m), 4.55 (3H, m), 4.40 (1H, m), 4.26 (1H, m), 4.15
(2H, m), 4.05 (1H, m), 3.96 (1H, m), 3.70 (1H, m), 2.24 (2H, t,
J=7.6 Hz), 1.55 (2H, m), 1.23 (28H, m), 0.86 (3H, t, J=6.8 Hz).
13C NMR (CDCl3): δ 173.35, 168.69, 155.79, 137.52, 137.46,
136.01, 135.33, 134.89, 128.65, 128.57, 128.46, 128.38, 128.35,
128.21, 128.14, 128.05, 127.93, 127.85, 127.80, 74.93, 74.86,
74.81, 72.04, 72.01, 69.66, 69.60, 67.64, 67.10, 66.53, 66.46,
62.15, 54.47, 54.41, 34.01, 31.86, 29.64, 29.60, 29.57, 29.42,
Compound 52.
Following the general procedure K, 48 (216.5 mg, 0.312 mmol),
CAN (427.8 mg, 0.780 mmol), and CH3CN-H2O (3 mL) were
used. The crude mixture was chromatographed (EtOAc/hexane
1:1 to 4:1) to yield the intermediate alcohol (142.8 mg, 0.243 mmol,
77%, brown oil). The obtained alcohol (140.3 mg, 0.239 mmol)

Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5851
was acylated with stearoyl chloride (79.6 mg, 0.263 mmol) in
CH2Cl2 (2.5 mL) in the presence of DMAP (87.5 mg, 0.716 mmol).
The crude mixture was chromatographed (EtOAc/hexane 1:3 to
Compound 38.
1
2:3) to yield 52 (155.9 mg, 0.183 mmol, 76%, colorless oil). H
NMR (CDCl3): δ 7.30 (15H, m), 5.90 (1H, m), 5.16 (2H, m), 5.09
(2H, m), 4.97 (2H, m), 4.58 (1H, m), 4.43 (1H, m), 4.30 (1H, m),
4.11 (1H, m), 4.05-3.90 (3H, m), 3.47 (1H, m), 3.35 (3H, s),
2.26 (2H, t, J=7.6 Hz), 1.55 (2H, m), 1.23 (28H, m), 0.86 (3H, t, J=
7.0 Hz). 13C NMR (CDCl3): δ 173.44, 168.75, 155.85, 136.05,
135.40, 134.93, 128.73, 128,63, 128.62, 128.50, 128.27, 128.19,
128.08, 128.01, 127.99, 69.70, 67.70, 67.45, 67.15, 66.36, 66.30,
65.84, 61.81, 58.01, 58.79, 54.52, 54.45, 34.04, 31.90, 29.68, 29.64,
29.60, 29.46, 29.34, 29.25, 29.10, 24.83, 22,67, 14.11. 31P NMR
(CDCl3): δ -0.34, -0.40. HRMS (ESI, [M þ Na]þ) Calcd for
C47H68NNaO11P: 876.4428. Found: 876.4391.
Following the general procedure G, 36 (807.7 mg, 4.08 mmol),
TBAI (451.7 mg, 1.22 mmol), DIPEA (1.58 g, 2.13 mL, 12.23
mmol), 4-methoxytritylchloride (1.384 g, 4.48 mmol), and CH2Cl2
(20 mL) were used. The crude mixture was chromatographed
(EtOAc/hexane 1:4 to 1:2) to yield 38 (1.68 g, 3.59 mmol, 88%,
yellow oil). 1H NMR (CDCl3): δ 7.41 (6H, m), 7.30-7.19 (8H, m),
6.80 (4H, m), 4.10 (1H, m), 3.99 (2H, m), 3.77 (3H, s), 3.75 (3H, s),
3.30 (2H, m). HRMS (ESI, [M þ Na]þ): Calcd for C30H30NaO5:
493.1991. Found: 493.1990.
Compound 6.
Compound 41.
Following the general procedure H, 38 (1.688 g, 3.59 mmol),
TBAI (397.4 mg, 1.08 mmol), NaH (391.2 mg, 8.97 mmol),
benzyl bromide (920.1 mg, 0.64 mL, 5.38 mmol), and THF (20
mL) were used. The crude mixture was chromatographed
(EtOAc/hexane 1:15 to 1:12) to yield 41 (1.772 g, 3.16 mmol,
88%, yellow oil). 1H NMR (CDCl3): δ 7.44 (4H, m), 7.32-7.19
(11H, m), 6.79 (8H, m), 4.66 (2H, m), 4.06 (2H, m), 3.88 (1H, m),
3.76 (3H, s), 3.74 (3H, s), 3.31 (2H, m). HRMS (ESI, [M þ
Na]þ): Calcd for C37H36NaO5: 583.2460. Found: 583.2461.
Compound 45.
Following the general procedure L, 52 (27.9 mg, 0.0326 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to7:2:1) and the product was washed with MeOH to yield 6
(8.0 mg, 0.0166 mmol, 51%, white powder). 1H NMR (CDCl3/
CD3CO2D 4:1): δ 4.85-4.34 (3H, m), 4.32-3.88 (5H, m), 3.51
(1H, m), 3.35 (3H, s) 2.23 (2H, m), 1.55 (2H, m), 1.08 (28H, m),
0.76 (3H, t, J = 7.0 Hz). HRMS (ESI, [M - H]-) Calcd for
C25H49NO9P: 538.3145. Found: 538.3131. Anal. Calcd for
C25H50NO9P þ CF3CO2H: C, 49.61; H, 7.86; N, 2.14. Found:
C, 49.56; H, 8.07; N, 2.22. mp 175.5-176.0 ꢀC.
Synthesis of Compound 7. Compound 34.
Following the general procedure J, 41 (1.66 g, 2.96 mmol),
p-toluenesulfonic acid (66.4 mg, 0.347 mmol), and CH2Cl2-
MeOH (40 mL) were used. The crude mixture was chromato-
graphed (EtOAc/hexane 3:7) to yield 45 (672.9 mg, 1.99 mmol,
67%, white solid). 1H NMR (CDCl3): δ 7.35-7.28 (5H, m), 6.81
(4H, m), 4.75(1H, m), 4.66 (1H, m), 4.03 (2H, m), 3.85 (1H, m),
3.82 (1H, m), 3.75 (3H, s), 3.73 (1H, m), 1.75 (1H, bs). HRMS
(ESI, [M þ Na]þ): Calcd for C17H20NaO4: 311.1259. Found:
311.1259. mp 44.5-45.0 ꢀC.
To a solution of (S)-(þ)-2,2-dimethyl-1,3-dioxolane-4-metha-
nol (1.33 g, 1.01 mmol), triphenylphosphine (3.13 g, 12.0 mmol),
and p-methoxyphenol (1.37 g, 1.10 mmol) in toluene (60 mL),
diethyl azodicarboxylate (DEAD) (2.2 M in toluene, 5.5 mL,
12.1 mmol) was added. The whole was warmed to 70 ꢀC, and
stirred for 2 h. The solvent was evaporated and the residue was
chromatographed (Et2O/hexane 1:15) to yield 34 (1.577 g, 6.63
Compound 49.
1
mmol, 66%, colorless oil). H NMR (CDCl3): δ 6.82 (4H, m),
4.43 (1H, m), 4.13 (1H, m), 4.02 (1H, m), 3.88 (1H, m), 3.85 (1H,
m), 3.74 (3H, s), 1.43 (3H, s), 1.38 (3H, s). HRMS (ESI, [M þ
Na]þ): Calcd for C13H18NaO4: 261.1103. Found: 261.1101.
Compound 36.
Following the general procedure B, 45 (87.6 mg, 0.304 mmol),
28 (204.0 mg, 0.360 mmol), 1H-tetrazole (57.8 mg, 0.825 mmol),
TBHP (0.25 mL, 1.50 mmol), CH2Cl2(0.75 mL), and THF
(1.6 5 mL) were used. The crude mixture was chromatographed
(EtOAc/hexane 1:6 to 1:2) to yield 49 (197.7 mg, 0.257 mmol, 85%,
colorless oil). A mixture of trans/cis isomers with respect to the
benzyloxycarbonylamino group was observed. 1H NMR (CDCl3):
δ 7.23-7.30 (20H, m), 6.76 (4H, m), 5.87 (1/2H, d, J=8.5 Hz), 5.76
(1/2H, d, J=8.5 Hz), 5.13 (2H, m), 5.07 (2H, m), 4.92 (2H, m), 4.62
(2H, m), 4.55 (1H, m), 4.39 (1H, m), 4.25 (1H, m), 4.21 (1H, m),
4.09(1H, m), 3.92(2H, m), 3.84(1H, m), 3.73(3H, s). HRMS(ESI,
[M þ Na]þ): Calcd for C42H44NNaO11P: 792.2550. Found:
792.2579.
To a solution of 34 (1.45 g, 6.09 mmol) in MeOH (160 mL),
Amberlyst-15 (792.7 mg) was added and the whole was stirred
for 1 d at room temperature. Amberlyst-15 was removed by
filtration and the solvent was evaporated. The residue was
chromatographed (EtOAc/hexane 2:1 to 4:1) to yield 36 (923.2
mg, 4.73 mmol, 78%, colorless oil). 1H NMR (CDCl3): δ 6.82
(4H, m), 4.07 (1H, m), 3.98 (2H, m), 3.81 (1H, m), 3.75 (3H, s),
3.72 (1H, m), 2.23 (2H, bs). HRMS (ESI, [M þ Na]þ): Calcd for
C10H14NaO4: 221.0790, Found: 221.0780. mp 71.5-72.0 ꢀC.

5852 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Iwashita et al.
Compound 53.
(5 mL) were used. The crude mixture was chromatographed (EtOAc/
hexane 3:7) to yield 46 (83.9 mg, 0.395 mmol, 80%, white solid). 1H
NMR (CDCl3):δ6.82(4H, m), 4.00(2H,m), 3.83(1H, m), 3.72(1H,
m), 3.64 (1H, m), 3.51 (3H, s). HRMS (ESI, [M þ Na]þ): Calcd for
C11H16NaO4: 235.0946. Found: 235.0939. mp 48.5-49.0 ꢀC.
Compound 50.
Following the general procedure K, 49 (102.0 mg, 0.133 mmol),
CAN (181.6 mg, 0.331 mmol), and CH3CN-H2O (5 mL) were used.
The crude mixture was chromatographed (EtOAc/hexane 2:3 to 7:3)
to yield the intermediate alcohol (75.4 mg, 0.114 mmol, 86%, brown
oil). The obtained alcohol (258.1 mg, 0.390 mmol) was acylated with
stearoyl chloride (141.9 mg, 0.468 mmol) in CH2Cl2 (1.5 mL) in the
presence of DMAP (142.6 mg, 1.167 mmol). The crude mixture was
chromatographed (EtOAc/hexane 1:3 to 2:3) to yield 53 (290.9 mg,
0.313 mmol, 80%, colorless oil). A mixture of trans/cis isomers with
Following the general procedure B, 46 (66.6 mg, 0.314 mmol), 28
(204.0 mg, 0.360 mmol), 1H-tetrazole (63.1 mg, 0.900 mmol),
TBHP (0.25 mL, 1.50 mmol), CH2Cl2 (1.2 mL), and THF
(1.8 mL) were used. The crude mixture was chromatographed
(EtOAc/hexane 2:3 f 1:1) to yield 50 (209.9 mg, 0.328 mmol, 97%,
colorless oil). 1H NMR (CDCl3): δ 7.30 (15H, m), 6.78 (4H, m),
5.92 (1H, m), 5.14 (2H, m), 5.08 (2H, m), 4.97 (2H, m), 4.57 (1H,
m), 4.42 (1H, m), 4.26 (1H, m), 4.20 (1H, m), 4.07 (1H, m), 3.90
(2H, m), 3.73 (3H, s), 3.62 (1H, m), 3.40 (3H, m). HRMS (ESI, [M
þ Na]þ): Calcd for C36H40NnaO11P: 716.2237. Found: 716.2238.
Compound 54.
1
respect to the benzyloxycarbonylamino group was observed. H
NMR (CDCl3): δ 7.25-7.32 (20H, m), 5.86 (1/2H, d, J=8.2 Hz),
5.79 (1/2H, d, J=8.2 Hz), 5.16 (2H, m), 5.08 (2H, m), 4.94 (2H, m),
4.57(3H, m), 4.40 (1H, m), 4.26 (1H, m), 4.18 (2H, m), 4.00(2H, m),
3.69 (1H, m), 2.24 (2H, m), 1.55 (2H, m), 1.23 (28H, m), 0.85 (3H, t,
J=6.8 Hz). 13C NMR (CDCl3): δ 173.38, 173.35, 168.69, 155.80,
137.51, 137.46, 135.99, 135.37, 135.30, 134.90, 128.65, 128.63, 128.56,
128.44, 128.34, 128.22, 128.13, 128.05, 127.92, 127.81, 127.78, 127.75,
77.20, 74.98, 74.91, 74.85, 74.78, 72.04, 71.95, 69.70, 69.63, 69.54,
67.64, 67.10, 66.48, 66.42, 62.17, 62.12, 54.46, 54.40, 33.99, 31.85,
29.63, 29.59, 29.56, 29.40, 29.29, 29.21, 29.07, 24.77, 22.62, 14.07. 31
P
NMR (CDCl3): δ -0.37, -0.39. HRMS (ESI, [M þ Na]þ) Calcd
for C53H72NNaO11P: 952.4741. Found: 952.4771.
Compound 7.
Following the general procedure K, 50 (146.2 mg, 0.211 mmol),
CAN (274.1 mg, 0.530 mmol), and CH3CN-H2O (3 mL) were
used. The crude mixture was chromatographed (EtOAc/hexane
1:1 to 4:1) to yield the intermediate alcohol (94.4 mg, 0.161 mmol,
76%, brown oil). The obtained alcohol (94.4 mg, 0.161 mmol) was
acylated with stearoyl chloride (53.6 mg, 0.177 mmol) in CH2Cl2
(2.5 mL) in the presence of DMAP (58.9 mg, 0.482 mmol). The
crude mixture was chromatographed (EtOAc/hexane 1:3 to 2:3) to
Following the general procedure L, 53 (63.0 mg, 0.0677 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to 7:2:1), and the product was washed with MeOH to yield
7 (27.0 mg, 0.0514 mmol, 75%, white powder). 1H NMR
(CDCl3/CD3CO2D 4:1): δ 4.59 (1H, m), 4.34 (1H, m), 4.17
(1H, m), 4.04 (2H, m), 3.90 (2H, m), 3.72(1H, m), 2.23 (2H, m),
1.55(2H, m), 1.08 (28H, m), 0.79 (3H, t, J=7.0 Hz). HRMS (ESI,
[M - H]-) Calcd for C24H47NO9P: 524.2988. Found: 524.2971.
1
yield 54 (112.8 mg, 0.132 mmol, 82%, colorless oil). H NMR
(CDCl3):δ7.31(15H, m), 5.88(1H, m), 5.16(2H, m), 5.09(2H, m),
4.96 (2H, m), 4.59 (1H, m), 4.42 (1H, m), 4.28 (1H, m), 4.14 (1H,
m), 4.04 (1H, m), 3.97 (1H, m), 3.47 (1H, m), 3.34 (3H, s), 2.27 (2H,
t, J=7.6 Hz), 1.55 (2H, m), 1.23 (28H, m), 0.86 (3H, t, J=7.0 Hz).
13C NMR (CDCl3): δ 173.46, 168.75, 155.86, 136.07, 135.42,
135.36, 134.91, 128.71, 128,62, 128.62, 128.49, 128.28, 128.18,
128.08, 128.01, 127.98, 69.66, 69.60, 67.72, 67.43, 67.15, 66.26,
66.20, 61.83, 61.75, 57.96, 54.46, 34.02, 31.89, 29.66, 29.63, 29.59,
29.45, 29.33, 29.24, 29.09, 24.82, 22,66, 14.09. 31P NMR (CDCl3):
δ -0.52, -0.54. HRMS (ESI, [M þ Na]þ) Calcd for C47H68-
NNaO11P: 876.4428. Found: 876.4439.
4
Anal. Calcd for C24H48NO9P þ /5CF3CO2H: C, 50.57; H, 8.15;
N, 2.33. Found: C, 50.31; H, 7.82; N, 2.32. mp 171.5-172.0 ꢀC.
Synthesis of Compound 8. Compound 42.
Compound 8.
Following the general procedure I, 38 (261.4 mg, 0.556 mmol),
NaH (74.2 mg, 1.70 mmol), methyl iodode (396.0 mg, 0.18 mL,
2.80 mmol), and THF (20 mL) were used. The crude mixture was
chromatographed (EtOAc/hexane 3:7) to yield 42 (256.0 mg, 0.527
mmol, 95%, yellow oil). 1H NMR (CDCl3): δ 7.42-7.27 (10H, m)
6.80 (8H, m), 4.08 (1H, m), 4.00 (1H, m), 3.77 (3H, s), 3.75 (3H, s),
3.64 (1H, m), 3.43 (3H, s), 3.28 (2H, m). HRMS (ESI, [M þ Na]þ):
Calcd for C31H32NaO5: 507.2147. Found: 507.2151.
Following the general procedure L, 54 (25.3 mg, 0.0296 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to 7:2:1) and the product was washed with MeOH to yield
8 (11.1 mg, 0.0206 mmol, 66%, white powder). 1H NMR (CDCl3/
CD3CO2D 4:1): δ 4.68 (2H, m), 4.55 (1H, m), 4.32 (3H, m), 4.27
(1H, m), 4.19 (1H, m), 3.84 (1H, m), 3.58 (3H, m), 2.19 (2H, m),
1.59 (2H, m), 1.23 (28H, m), 0.85 (3H, t, J=6.8 Hz). HRMS (ESI,
[M - H]-) Calcd for C25H49NO9P: 538.3145. Found: 538.3132.
Compound 46.
1
Following the general procedure J, 42 (239.4 mg, 0.493 mmol),
p-toluenesulfonic acid (9.5 mg, 0.0450 mmol), and CH2Cl2-MeOH
Anal. Calcd for C25H50NO9Pþ /2CF3CO2H: C, 52.34; H, 8.53; N,
2.34. Found: C, 52.30; H, 8.36; N, 2.29. mp 179.0-179.5 ꢀC.

Article
Synthesis of Amide Analogues 9 and 10 (Scheme 3). Synthesis
of Compound 9. Compound 55.
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5853
(5 mL) were used. The crude mixture was chromatographed
(EtOAc/hexane 1:1 to 3:2) to yield 59 (179.1 mg, 0.400 mmol,
80%, white solid). 1H NMR (CDCl3): δ 7.35-7.29 (5H, m), 5.73
(1H, m), 4.57 (2H, dd, J=15.2 Hz, 6.0 Hz), 3.70-3.55 (3H, m),
3.52-3.45 (1H, m), 3.36-3.28 (1H, m), 2.15 (2H, t, J=7.6 Hz),
1.59 (2H, m), 1.23 (28H, m), 0.86 (3H, t, J=7.0 Hz). HRMS (ESI,
[M þ Na]þ): Calcd for C28H49NNaO3: 470.3610. Found:
470.3615. mp 109.0-109.5 ꢀC.
Compound 61.
To a preheated solution (at 50 ꢀC) of (R)-3-amino-1,2-propanediol
(281.8 mg, 3.09 mmol) and pyridine (1 mL) in DMF (20 mL), a
solution of stearoyl chloride (1.030 g, 3.042 mmol) in DMF (10 mL)
was added and the whole was stirred for 3 h. The organic solvent was
evaporated, and the residue was chromatographed (CHCl3/MeOH
1:0 to 9:1) to yield 55 (638.2 mg, 1.79 mmol, 58%, white solid). 1H
NMR (CDCl3): δ 4.74 (1H, bs), 3.74 (1H, m), 3.54 (2H, m), 3.40
(2H, m), 2.20 (2H, t, J=7.6 Hz), 1.54 (2H, m), 1.23 (28H, m), 0.86
(3H, t, J = 6.8 Hz). HRMS (ESI, [M þ Na]þ): Calcd for
C21H43NNaO3: 380.3141. Found: 380.3141. mp 109.0-109.5 ꢀC.
Compound 56.
Following the general procedure B, 59 (45.0 mg, 0.0991 mmol),
28 (67.7 mg, 0.119 mmol), 1H-tetrazole (23.3 mg, 0.332 mmol),
TBHP (0.08 mL, 0.480 mmol), CH2Cl2 (0.4 mL), and THF
(0.6 mL) were used. The crude mixture was chromatographed
(EtOAc/hexane 3:7) to yield 61 (71.4 mg, 0.328 mmol, 77%,
1
colorless oil). H NMR (CDCl3): δ 7.31-7.25 (20H, m), 6.00
(1H, dd, J=8.0 Hz, 4.0 Hz), 5.15 (2H, m), 5.08 (2H, m), 4.96
(2H, m), 4.62-4.53 (2H, m), 4.47-4.39 (2H, m), 4.30 (1H, m),
4.24 (1H, m), 4.06-3.88 (2H, m), 3.64-3.55 (1H, m), 3.41-3.32
(1H, m), 3.30-3.23 (1H, m), 2.00 (2H, m), 1.55 (2H, m), 1.23
(28H, m), 0.86 (3H, t, J=7.0 Hz). 13C NMR (CDCl3): δ 173.41,
173.30, 170.13, 168.73, 155.79, 137.53, 137.33, 136.31, 135.99,
135.18, 134.89, 128.73, 128.61, 128.57, 128.47, 128.38, 128.34,
128.29, 128.19, 128.04, 127.98, 127.94, 127.91, 127.85, 127.77,
127.44, 75.37, 71.90, 71.82, 69.73, 67.77, 67.13, 66.77, 65.01,
62.30, 54.50, 54.42, 40.48, 39.10, 39.03, 36.49, 33.85, 31.86,
29.65, 29.60, 29.47, 29.44, 29.30, 29.26, 25.56, 24.72, 22.63,
14.07. 31P NMR (CDCl3): δ -0.30. HRMS (ESI, [M þ Na]þ):
Calcd for C53H73N2NaO10P: 951.4901. Found: 951.4869.
Compound 9.
To a preheated solution (at 50 ꢀC) of 55 (603.5 mg, 1.69 mmol),
TBAI (198.9 mg, 0.537 mmol), and DIPEA (0.88 mL, 654.4 mg,
5.06 mmol) in THF (20 mL), 4-methoxy tritylchloride (576.5 mg,
1.87 mmol) was added and the whole was heated at 50 ꢀC with
stirring for 2 h. The whole was cooled to room temperature, and
the reaction was quenched with 3N aqueous HCl. The obtained
organic layer was washed with 3N aqueous HCl and brine and was
dried over Na2SO4. The solvent was evaporated, and the residue
was chromatographed (EtOAc/hexane 1:2) to yield 56 (877.8 mg,
1.394 mmol, 83%, yellow oil). 1H NMR (CDCl3): δ 7.39 (4H, m),
7.29-7.20 (8H, m), 6.82 (2H, m), 5.63 (1H, m), 3.87 (1H, m),
3.78 (3H, s), 3.54 (1H, m), 3.24-3.10 (3H, m), 2.05 (2H, t, J=
7.6 Hz), 1.52 (2H, m), 1.23 (28H, m), 0.86 (3H, t, J=6.8 Hz).
HRMS (ESI, [M þ H]þ): Calcd for C41H59NNaO4: 652.4342.
Found: 652.4368. mp 47.5-48.0 ꢀC.
Compound 57.
Following the general procedure L, 61 (31.8 mg, 0.0343 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to 7:2:1) to yield 9 (14.0 mg, 0.0267 mmol, 78%, white
powder). 1H NMR (CDCl3/CD3CO2D 4:1): δ 4.39 (3H, m), 3.89
(3H, m), 3.16 (3H, m), 2.13 (2H, m), 1.49 (2H, m), 1.17 (28H, m),
0.79 (3H, t, J=6.8 Hz). HRMS (ESI, [M - H]-): Calcd for
C24H48N2O8P: 523.3148. Found: 523.3154. Anal. Calcd for
C24H49N2O8P þ 5/6CF3CO2H: C, 49.75; H, 8.11; N, 4.52.
Found: C, 49.84; H, 8.33; N, 4.73. mp 180.5-181.0 ꢀC.
Synthesis of Compound 10. Compound 58.
Following the general procedure H, 56 (1.53 g, 2.43 mmol), NaH
(127.1 mg, 2.91 mmol), benzyl bromide (435.9 mg, 2.55 mmol), and
THF (40 mL) were used. The crude mixture was chromatographed
(EtOAc/hexane 1:10 to 1:5) to yield 57 (1.669 g, 2.32 mmol, 95%,
yellow oil). 1H NMR (CDCl3): δ 7.20-7.35 (17H, m), 6.82 (2H,
m), 5.72 (1H, m), 4.57 (2H,dd, J=15.2 Hz, 5.6 Hz,), 3.78 (3H, s)
3.55-3.70 (3H, m), 3.48 (1H, m), 3.29 (1H, m), 2.16 (2H, t, J=7.6
Hz), 1.57 (2H, m), 1.23 (28H, m), 0.86 (3H, t, J=6.8 Hz). HRMS
(ESI, [M þ Na]þ): Calcd for C48H65NNaO4: 742.4811. Found:
742.4813. mp 66.5-67.0 ꢀC.
Compound 59.
Following the general procedure I, 57 (338.6 mg, 0.470 mmol),
NaH (33.8 mg, 0.740 mmol), methyl iodode (80.1 mg, 0.564
mmol), and THF (20 mL) were used. The crude mixture was
chromatographed (EtOAc/hexane 3:7) to yield 58 (220.9 mg,
0.301 mmol, 64%, yellow oil). 1H NMR (CDCl3): δ 7.47-7.41
(4H, m), 7.35-7.20 (13H, m), 6.82 (2H, m), 4.70-4.30 (2H, m),
3.87 (1H, m), 3.76 (3H, m), 3.55 (1H, m), 3.45 (1H, m),
3.40-3.18 (2H, m), 2.90-2.81 (3H, m), 2.30-2.16 (2H, m),
Following the general procedure J, 57 (357.5 mg, 0.497 mmol),
p-toluenesulfonic acid (8.6 mg, 0.0410 mmol), and CH2Cl2-MeOH

5854 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Iwashita et al.
1.54 (2H, m), 1.23 (28H, m), 0.86 (3H, t, J=6.8 Hz). HRMS
Synthesis of LysoPT Analogues 11 and 12 (Scheme 4). Synthesis of
Compound 11 (LysoPT). Compound 65.
(ESI, [M þ Na]þ): Calcd for C49H67NNaO4: 756.4968. Found:
756.4969.
Compound 60.
Following the general procedure A, N-Z-L-threonine benzyl ester
(63, 515.3 mg, 1.50 mmol), 27 (511.4 mg, 1.55 mmol), 1H-tetrazole
(105.1 mg, 1.50 mmol), CH2Cl2 (12 mL), and THF (3 mL) were
used. The crude mixture was chromatographed (EtOAc/hexane/
Et3N 100:0:3 to 20:80:3) to yield 65 (609.0 mg, 1.05 mmol, 70%,
colorless oil). 1H NMR (CD2Cl2): δ 7.33 (15H, m), 5.58 (1/2H, d,
J=9.2 Hz), 5.48 (1/2H, d, J=9.2 Hz), 5.09 (4H, m), 4.67 (1H, m),
4.57 (2H, m), 4.33 (1H, m), 3.57 (2H, m), 1.28 (3H, m), 1.14 (12H,
m). 13C NMR (CDCl3): δ 171.38, 170.29, 157.01, 156.65, 142.02,
138.26, 138.19, 136.87, 136.70, 135.95, 135.88, 135.55, 128.51,
128.47, 128.43, 128.39, 128.28, 128.24, 128.19, 128.12, 128.06,
128.01, 127.90, 127.59, 127.43, 126.94, 126.77, 67.42, 67.15,
66.97, 66.82, 66.77, 66.59, 65.70, 65.66, 64.11, 46.44, 20.08, 18.74,
18.72. 31P NMR (CDCl3): δ 2.79, 1.60. HRMS (ESI, [M þ Na]þ):
Calcd for C32H41N2NaO3P: 603.2600. Found: 603.2586.
Compound 67.
Following the general procedure J, 58 (221.8 mg, 0.302 mmol),
p-toluenesulfonic acid (15.4 mg, 0.0730 mmol), and CH2Cl2-
MeOH (5 mL) were used. The crude mixture was chromato-
graphed (EtOAc/hexane 1:4f1:3) to yield 60 (122.3 mg, 0.265
mmol, 88%, white solid). 1H NMR (CDCl3): δ 7.35-7.23
(5H, m), 4.58 (2H, m), 3.90 (1H, m), 3.64 (1H, m), 3.55 (1H,
m), 3.42 (1H, m), 3.30 (1H, m), 3.06 (3H, s), 2.31 (2H, m), 1.54
(2H, m), 1.23 (28H, m), 0.86 (3H, t, J=6.8 Hz). HRMS (ESI, [M
þ Na]þ): Calcd for C29H51NNaO3: 484.3767. Found: 484.3767.
mp 34.0-34.5 ꢀC.
Compound 62.
Following the general procedure B, using 60 (45.5 mg, 0.0985
mmol), 28 (67.6 mg, 0.119 mmol), 1H-tetrazole (20.6 mg, 0.294
mmol), TBHP (0.08 mL, 0.48 mmol), CH2Cl2 (0.4 mL), and THF
(0.6 mL). The crude mixture was chromatographed (EtOAc/hexane
3:7) to yield 62 (56.9 mg, 0.0594 mmol, 60%, colorless oil). A
mixture of trans/cis isomers with respect to the benzyloxycarbonyl-
amino group was observed. 1H NMR (CDCl3): δ 7.31-7.25 (20H,
m), 6.11 (1/2H, d, J=4.0Hz), 6.01(1/2H, d, J=4.0 Hz), 5.15 (2H, m),
5.08(2H, m), 4.96 (2H, m), 4.58 (2H, m), 4.40 (2H, m), 4.27 (1H, m),
4.10 (1H, m), 3.90 (2H, m), 3.57 (1H, m), 3.15 (1H, m), 2.87-2.75
(3H, m), 2.15 (2H, m), 1.55 (2H, m), 1.23 (28H, m), 0.86 (3H, t,
J=7.0 Hz). 13C NMR (CDCl3): δ 173.49, 173.18, 169.71, 168.72,
156.17, 155.90, 137.82, 137.33, 136.26, 136.05, 135.25, 134.94,
128.61, 128.56, 128.51, 128.44, 128.40, 128.36, 128.29, 128.25,
128.16, 128.0, 128.01, 127.95, 127.90, 127.87, 127.79, 127.72,
127.44, 75.94, 73.02, 72.05, 71.89, 69.53, 67.54, 66.77, 65.44, 64.89,
62.07, 55.14, 54.43, 49.96, 49.40, 37.57, 33.85, 33.60, 33.41, 31.82,
Following the general procedure B, 43 (153.6 mg, 0.507 mmol),
65 (344.2 mg, 0.594 mmol), 1H-tetrazole (105.8 mg, 1.51 mmol),
TBHP (0.42 mL, 2.52 mmol), CH2Cl2 (2 mL), and THF (3 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 1:3) to yield 67 (392.2 mg, 0.501 mmol, 99%, colorless
oil). 1H NMR (CDCl3): δ 7.30 (20H, m), 6.75 (4H, m), 5.09 (2H,
m), 5.03 (2H, m), 4.93 (3H, m), 4.44 (1H, m), 4.16 (1H, m), 4.09
(1H, m), 3.93 (2H, m), 3.84 (1H, m), 3.73 (3H, m), 1.33 (3H, m).
13C NMR (CDCl3): δ 169.05, 169.02, 156.21, 153.74, 152.21,
152.19, 137.52, 1237.51, 135.78, 135.77, 135.34, 135.31, 135.27,
135.25, 134.71, 134.67, 128.22, 128.16, 128.05, 128.00, 127.84,
127.71, 127.57, 127.52, 127.49, 127.45, 115.17, 115.14, 114.28,
77.60, 77.32, 77.20, 77.00, 76.68, 75.36, 75.28, 75.24, 75.17,
75.12, 75.06, 71.91, 71.89, 71.81, 69.12, 69.10, 69.06, 69.05,
68.10, 67.31, 67.29, 66.86, 66.37, 66.31, 66.25, 65.42, 61.80,
58.33, 58.26, 58.20, 55.22, 18.12, 14.95. 31P NMR (CDCl3): δ
-1.34. HRMS (ESI, [M þ Na]þ): Calcd for C43H46NNaO11P:
806.2706. Found: 806.2692.
29.61, 29.56, 29.47, 29.39, 29.27, 29.21, 24.80, 24.72, 22.60, 14.04. 31
P
NMR (CDCl3): δ -0.16. HRMS (ESI, [M þ Na]þ): Calcd for
C54H75N2NaO10P: 965.5057. Found: 965.5090.
Compound 10.
Compound 69.
Following the general procedure L, 62 (35.0 mg, 0.0371 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to 7:2:1) and the product was washed with MeOH to yield
10 (13.2 mg, 0.0245 mmol, 66%, white powder). 1HNMR(CDCl3/
CD3CO2D 4:1): δ 4.40 (3H, m), 3.96 (3H, m), 3.50 (3H, m),
3.11-2.75 (3H, m), 2.27-2.13 (2H, m), 1.49 (2H, m), 1.17 (28H,
m), 0.79 (3H, t, J=6.8 Hz). HRMS (ESI, [M - H]-): Calcd for
C24H48N2O8P: 537.3305. Found: 537.3326. Anal. Calcd for
C24H49N2O8P þ CF3CO2H: C, 49.69; H, 8.03; N, 4.29. Found:
C, 49.84; H, 8.30; N, 4.00. mp 174.0-174.5 ꢀC.
Following the general procedure K, 67 (250.1 mg, 0.319 mmol),
CAN (441.4 mg, 0.805 mmol), and CH3CN-H2O (3 mL) were
used. The crude mixture was chromatographed (EtOAc/hexane
1:1 to 4:1) to yield the intermediate alcohol (154.6 mg, 0.228
mmol, 71%, brown oil). The obtained alcohol (154.6 mg, 0.228
mmol) was acylated with stearoyl chloride (76.1 mg, 0.251
mmol) in CH2Cl2 (2.5 mL), in the presence of DMAP (82.1
mg, 0.672 mmol). The crude mixture was chromatographed
(EtOAc/hexane 1:3 to 2:3) to yield 69 (192.7 mg, 0.204 mmol,
1
90%, colorless oil). H NMR (CDCl3): δ 7.31 (20H, m), 5.88
(1H, m), 5.16 (2H, m), 5.09 (2H, m), 4.96 (2H, m), 4.59 (1H, m),

Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5855
4.42 (1H, m), 4.28 (1H, m), 4.14 (1H, m), 4.04 (1H, m), 3.97 (1H,
m), 3.47 (1H, m), 3.34 (3H, s), 2.27 (2H, t, J =7.6 Hz), 1.55
(2H, m), 1.36 (3/2H, d, J=6.4 Hz), 1.31 (3/2H, d, J=6.4 Hz), 1.23
(28H, m), 0.86 (3H, t, J=7.0 Hz). 13C NMR (CDCl3): δ 173.38,
173.22, 168.46, 168.43, 165.50, 155.85, 137.71, 136.15, 135.60,
135.54, 134.96, 129.83, 129.80, 128.59, 128.57, 128.48, 128.35,
128.21, 128.13, 128.09, 127.89, 127.86, 127.84, 127.81, 127.78,
77.21, 75.91, 75.85, 75.76, 75.10, 75.02, 74.95, 72.11, 72.05,
74.95, 72.11, 72.05, 69.63, 69.61, 69.58, 69.55, 67.51, 67.50,
67.10, 66.54, 66.49, 62.33, 62.29, 58.61, 34.06, 33.99, 31.90,
29.68, 29.64, 29.61, 29.46, 29.34, 29.27, 29.13, 24.83, 24.67,
18.49, 18.44, 14.10. 31P NMR (CDCl3): δ -1.29, -1.35. HRMS
(ESI, [M þ Na]þ): Calcd for C57H74NNaO11P: 966.4897.
Found: 966.4909.
(CD2Cl2): δ 7.33 (15H, m), 6.19 (1/2H, m), 5.61 (1/2H, m),
5.22-5.09 (4H, m), 4.76 (1H, m), 4.59 (2H, m), 4.38 (1H, m),
4.28 (1H, m) 3.58 (2H, m), 1.33 (3H, m), 1.14 (12H, m). HRMS
(ESI, [M þ Na]þ): Calcd for C32H41N2NaO3P: 603.2600.
Found: 603.2598.
Compound 68.
Following the general procedure B, 43 (100.8 mg, 0.333 mmol),
66 (160.9 mg, 0.277 mmol), 1H-tetrazole (48.5 mg, 0.693 mmol),
TBHP (0.11 mL, 0.66 mmol), CH2Cl2 (1 mL), and THF (1.5 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 1:2) to yield 68 (85.0 mg, 0.108 mmol, 39%, colorless oil).
1H NMR (CDCl3): δ 7.27 (20H, m), 6.75 (4H, m), 6.12 (1H, m),
5.13-4.93 (6H, m), 4.73 (1H, m), 4.63 (2H, m), 4.49 (1H, m),
4.22 (1H, m), 4.09 (1H, m), 3.99-3.85 (3H, m), 3.73 (3H, m),
Compound 11 (LysoPT).
1.24 (3H, m). HRMS (ESI, [M
C43H46NNaO11P: 806.2706. Found: 806.2718.
Compound 70.
þ
Na]þ): Calcd for
Following the general procedure L, 69 (46.8 mg, 0.0496 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to 7:2:1), and washed with MeOH to yield 11 (17.7 mg,
0.0327 mmol, 66%, white powder). 1H NMR (CDCl3/CD3CO2-
D 4:1): δ 4.79 (1H, m), 4.04-3.80 (6H, m), 2.24 (2H, m), 1.49
(2H, m), 1.17 (35H, m), 0.78 (3H, t, J=6.8 Hz). HRMS (ESI,
[M - H]-): Calcd for C25H49NO9P: 538.3145. Found: 538.3141.
Anal. Calcd for C25H50NO9P þ CF3CO2H: C, 49.46; H, 7.85; N,
2.42. Found: C, 49.61; H, 7.85; N, 2.42. mp 176.5-177.0 ꢀC.
Synthesis of Compound 12 (LysoPalloT). Compound 64.
Following the general procedure K, 68 (208.5 mg, 0.271 mmol),
CAN (371.3 mg, 0.677 mmol), and CH3CN-H2O (6 mL) were
used. The crude mixture was chromatographed (EtOAc/
hexane 1:1 to 4:1) to yield the intermediate alcohol (145.5 mg,
0.215 mmol, 79%, brown oil). The obtained alcohol (145.5 mg,
0.215 mmol) was acylated with stearoyl chloride (78.2 mg, 0.258
mmol) in CH2Cl2 (5 mL) in the presence of DMAP (78.8 mg,
0.645 mmol). The crude product was chromatographed
(EtOAc/hexane 1:3 to 2:3) to yield 70 (180.5 mg, 0.191 mmol,
89%, colorless oil). 1H NMR (CDCl3): δ 7.28 (20H, m),
6.09(1H, m), 5.15 (2H, m), 5.07 (2H, m), 4.97 (2H, m), 4.73
(1H, m), 4.56 (2H, m), 4.16 (1H, m), 4.07 (2H, m), 3.95 (1H, m),
3.70 (1H, m), 2.24 (2H, t, J=7.6 Hz), 1.55 (2H, m), 1.34 (3H, t,
J=6.4 Hz), 1.23 (28H, m), 0.86 (3H, t, J=7.0 Hz). 13C NMR
(CDCl3): δ 173.39, 168.42, 155.84, 137.68, 137.54, 136.13,
135.52, 134.94, 128.59, 128.56, 128.47, 128.38, 128.35, 128.13,
128.09, 127.88, 127.81, 127.78, 75.82, 75.06, 74.99, 74.91, 72.09,
72.03, 69.59, 67.49, 67.09, 66.46, 62.27, 58.59, 34.05, 31.89,
29.67, 29.63, 29.60, 29.45, 29.33, 29.26, 29.12, 24.81, 22.66,
14.10. 31P NMR (CDCl3): δ -1.29, -1.35. HRMS (ESI, [M þ
Na]þ): Calcd for C57H74NNaO11P: 966.4897. Found: 966.4916.
Compound 12 (LysoPalloT).
Following the general procedure E, L-allo-threonine (101.4 mg,
0.851 mmol), benzyl chloroformate (174.3 mg, 1.021 mmol),
saturated aqueous NaHCO3 (10 mL), and THF (10 mL) were
used. The crude mixture was chromatographed (CHCl3/MeOH
1:0 to 9:1) to yield N-Z-L-allo-threonine (221.3 mg, 0.874 mmol,
quantitative yield, pale-yellow oil). The following benzylation
was carried out in accordance with the general procedure
F, which involved the intermediate alcohol (221.3 mg, 0.874
mmol), benzyl bromide (179.4 mg, 1.049 mmol), triethylamine
(0.43 mL, 2.621 mmol), and THF (10 mL). The crude mixture
was chromatographed (EtOAc/hexane 1:3) to yield 64 (213.0
mg, 0.620 mmol, 73% (in 2 steps), white solid). 1H NMR
(CDCl3): δ 7.33 (10H, m), 5.65 (1H, m), 5.18 (1H, m), 5.10
(2H, m), 4.47 (1H, m), 4.15 (1H, m), 1.13 (3H, d, J=6.4 Hz).
HRMS (ESI, [M þ Na]þ): Calcd for C19H21NNaO5: 366.1317.
Found: 366,1317. mp 74.0-74.5 ꢀC.
Compound 66.
Following the general procedure L, 70 (41.0 mg, 0.0435 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to 7:2:1) to yield 12 (12.6 mg, 0.0159 mmol, 37%, white
powder). 1H NMR (CDCl3/CD3CO2D 4:1): δ 4.23 (2H, m), 4.05
(5H, m), 2.24 (2H, m), 1.52(2H, m), 1.17 (31H, m), 0.79 (3H, t,
J=6.8 Hz). HRMS (ESI, [M - H]-): Calcd for C25H49NO9P:
538.3145. Found: 538.3137. mp 179.0-179.5 ꢀC.
Following the general procedure A, 64 (197.7 mg, 0.576 mmol),
27 (190.0 mg, 0.576 mmol), 1H-tetrazole (40.3 mg, 0.576 mmol),
CH2Cl2 (5 mL), and THF (1.2 mL) were used. The crude mixture
was chromatographed (EtOAc/hexane/Et3N 100:0:3 to 20:80:3)
to yield 66 (175.7 mg, 0.303 mmol, 53%, colorless oil). 1H NMR

5856 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Iwashita et al.
Synthesis of Compounds 13 and 14 (Scheme 5). Synthesis of
Compound 13. Compound 71.
4.24(1H,m),4.18(1H,m),4.10(1H, m),4.01(1H, m),3.70(4H, m),
2.25 (2H, t, J=7.6 Hz), 1.53 (2H, m), 1.23 (28H, m), 0.86 (3H, t, J=
7.2 Hz). 13C NMR (CDCl3): δ 173.40, 169.27, 155.81, 137.55,
137.50, 136.06, 135.42, 135.36, 128.72, 128.70, 128.62, 128.50,
128.41, 128.39, 128.19, 128.09, 127.96, 127.89, 127.86, 127.83,
77.21, 75.01, 74.97, 74.94, 74.90, 72.11, 69.73, 69.69, 67.38, 67.16,
66.60, 66.54, 66.48, 65.82, 62.21, 54.37, 54.30, 52.81, 34.05, 31.89,
29.67, 29.63, 29.60, 29.45, 29.33, 29.25, 29.12, 24.82, 22.66, 15.24,
14.09. 31PNMR(CDCl3):δ-0.34. HRMS (ESI, [M þ Na]þ) Calcd
for C47H68NNaO11P: 876.4428. Found: 876.4404.
Following the general procedure E, L-serine methyl ester hydro-
chloride (1.56 g, 10.0 mmol), benzyl chloroformate (2.05 g, 12.0
mmol), saturated aqueous NaHCO3 (50 mL), and THF (50 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 1:1) to yield 71 (2.143 g, 8.462 mmol, 84.6%, colorless oil).
1H NMR (CDCl3): δ 7.33 (5H, m), 5.69 (1H, m), 5.10 (2H, m),
4.43 (1H, m), 3.96 (1H, m), 3.90 (1H, m), 3.76 (3H, s). HRMS (ESI,
[M þ Na]þ): Calcd for C12H15NNaO5: 276.0848. Found: 276.0849.
Compound 72.
Compound 13.
Following the general procedure L, 74 (28.5 mg, 0.0333 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to 7:2:1) to yield 13 (10.3 mg, 0.0190 mmol, 57%, white
powder). 1H NMR (CDCl3/CD3CO2D 4:1): δ 4.55 (1H, m), 4.38
(2H, m), 4.04 (5H, m), 3.78 (3H, s), 2.25(2H, m), 1.52(2H, m), 1.17
(28H, m), 0.78 (3H, t, J=6.8 Hz). HRMS (ESI, [M - H]-): Calcd
for C25H49NO9P: 538.3145. Found: 538.3127. mp 150.5-151.0 ꢀC.
Synthesis of Compound 14. Compound 76.
Following the general procedure A, 71 (199.1 mg, 0.603 mmol), 27
(201.9 mg, 0.612 mmol), 1H-tetrazole (42.1 mg, 0.603 mmol), CH2Cl2
(5 mL), and THF (1.2 mL) were used. The crude mixture was
chromatographed (EtOAc/hexane/Et3N 100:0:3 to 20:80:3) to yield
72 (173.7 mg, 0.355 mmol, 59%, colorless oil). A mixture of trans/cis
isomers with respect to the benzyloxycarbonylamino group was
observed. 1H NMR (CD2Cl2): δ 7.31 (15H, m), 5.80 (1/2H, m), 5.62
(1/2H, m), 5.10 (2H, m), 4.65 (2H, m). 4.46(2H, m), 4.10(1H, m), 3.87
(1H, m), 3.71 (3H, m), 3.60 (2H, m), 1.16 (12H, m). HRMS (ESI,
[M þ Na]þ): Calcd for C25H35N2NaO6P: 513.2130. Found: 513.2109.
Compound 73.
Following the general procedure F, 75 (524.6 mg, 2.07 mmol),
benzyl bromide (576.0 mg, 3.37 mmol), TBAI (229.4 mg, 0.621
mmol), triethylamine (1.05 mL, 6.21 mmol), and THF (30 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 1:3 to 1:1) to yield 76 (545.8 mg, 1.59 mmol, 56% (2 steps),
white solid). 1H NMR (CDCl3): δ 7.32 (10H, m), 5.22-4.98 (4H,
m), 4.55-4.48 (1H, m), 4.08 (1H, m), 3.91-3.85 (1H, m), 2.95 (3H,
m). HRMS (ESI, [M þ Na]þ): CalcdforC19H21NNaO5: 366.1317.
Found: 363.1329.
Following the general procedure B, 43 (115.1 mg, 0.380 mmol),
72 (156.3 mg, 0.319 mmol), 1H-tetrazole (65.4 mg, 0.934 mmol),
TBHP (0.16 mL, 0.96 mmol), CH2Cl2 (2 mL), and THF (2 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 1:2 to 1:1) to yield 73 (145.3 mg, 0.209 mmol, 66%,
colorless oil). 1H NMR (CDCl3): δ 7.29 (15H, m), 6.77 (4H, m),
5.82 (1H, m), 5.08 (2H, m), 4.99 (2H, m), 4.66 (2H, m), 4.51 (1H,
m), 4.38 (1H, m), 4.26 (2H, m), 4.13 (1H, m), 3.92 (2H, m), 3.86
(1H, m), 3.73 (3H, m), 3.69 (3H, m). HRMS (ESI, [M þ Na]þ):
Calcd for C36H40NNaO11P: 716.2237. Found: 716.2238.
Compound 74.
Compound 77.
Following the general procedure A, 76 (172.8 mg, 0.524 mmol),
27 (162.3 mg, 0.492 mmol), 1H-tetrazole (35.1 mg, 0.500 mmol),
CH2Cl2 (4 mL), and THF (1 mL) were used. The crude mixture
was chromatographed (EtOAc/hexane/Et3N 100:0:3 to 20:80:3)
to yield 77 (184.2 mg, 0.318 mmol, 65%, colorless oil). 1H NMR
(CD2Cl2): δ 7.31 (15H, m), 5.20-4.94 (5H, m), 4.83 (1H, m),
4.67 (1H, m), 4.09 (1H, m), 3.59 (2H, m), 3.40 (1H, m),
3.00-2.89 (3H, m), 1.20 (12H, m). HRMS (ESI, [M þ Na]þ):
Calcd for C32H41N2NaO6P: 603.2600. Found: 603.2600.
Compound 78.
Following the general procedure K, 73 (127.0 mg, 0.183 mmol),
CAN (258.7 mg, 0.472 mmol), and CH3CN-H2O (6 mL) were used.
The crude mixture was chromatographed (EtOAc/hexane 1:1 to 4:1)
to yield the intermediate alcohol (79.9 mg, 0.136 mmol, 74%, brown
oil). The obtained alcohol (79.9 mg, 0.136 mmol) was acylated with
stearoyl chloride (49.4 mg, 0.163 mmol) in CH2Cl2 (5 mL) in the
presence of DMAP (33.2 mg, 0.272 mmol). The crude mixture was
chromatographed (EtOAc/hexane 1:3 to 1:2) to yield 74 (98.3 mg,
0.115 mmol, 85%, colorless oil) 1HNMR(CDCl3):δ7.32 (15H, m),
5.80(1H, m),5.09(2H, m),5.00(2H, m), 4.58(2H, m), 4.37(1H, m),
Following the general procedure B, 43 (96.0 mg, 0.317 mmol),
77 (153.2 mg, 0.264 mmol), 1H-tetrazole (55.5 mg, 0.793 mmol),

Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5857
TBHP (0.25 mL, 1.50 mmol), CH2Cl2 (2 mL), and THF (1.5 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 1:3 to 1:1) to yield 78 (173.9 mg, 0.222 mmol, 84%,
colorless oil). 1H NMR (CDCl3): δ 7.27 (20H, m), 6.76 (4H, m),
5.16-4.94 (6H, m), 4.81 (1H, m), 4.64 (2H, m), 4.42 (3/2H, m),
4.22 (3/2H, m), 4.11 (1H, m), 3.94 (2H, m), 3.86 (1H, m), 3.73
(3H, m), 2.89 (3H, s). HRMS (ESI, [M þ Na]þ): Calcd for
C43H46NNaO11P: 806.2706. Found: 806.2707.
benzyl bromide (523.4 mg, 3.06 mmol), triethylamine (1.1 mL,
6.53 mmol), and THF (10 mL). The crude mixture was chromato-
graphed (EtOAc/hexane 2:3) to yield 80 (213.0 mg, 0.620 mmol,
quantitative yield, colorless oil). 1H NMR (CDCl3): δ 7.32 (10H,
m), 5.15 (2H, m), 5.04 (2H, m), 4.43 (1H, m), 4.40-4.31 (1H, m),
3.68 (2H, m), 2.08 (1H, m), 1.92 (1H, m). HRMS (ESI, [M þ
Na]þ): Calcd for C20H21NNaO5: 378.1317. Found: 378.1317.
Compound 81.
Compound 79.
Following the general procedure K, 78 (107.3 mg, 0.134 mmol),
CAN (184.3 mg, 0.336 mmol), and CH3CN-H2O (2 mL) were
used. The crude mixture was chromatographed (EtOAc/hexane
1:1 to 4:1) to yield the intermediate alcohol (53.5 mg, 0.0773 mmol,
58%, brown oil). The obtained alcohol (53.5 mg, 0.0773 mmol)
was acylated with stearoyl chloride (28.1 mg, 0.0928 mmol) in
CH2Cl2 (5 mL) in the presence of DMAP (18.9 mg, 0.155 mmol).
The crude mixture was chromatographed (EtOAc/hexane 1:3) to
Following the general procedure A, 80 (217.5 mg, 0.612 mmol), 27
(200.0 mg, 0.612 mmol), 1H-tetrazole (42.1 mg, 0.600 mmol), CH2Cl2
(5 mL), and THF (1.2 mL) were used. The crude mixture was chro-
matographed (EtOAc/hexane/Et3N 100:0:3 to 20:80:3) to yield 81 (191.8
mg, 0.324 mmol, 54%, colorless oil). 1H NMR (CD2Cl2): δ 7.32 (15H,
m), 5.16-5.03 (4H, m), 4.95 (1H, m), 4.67 (2H, m), 4.51 (2H, m), 3.67
(1H, m), 3.60 (2H, m), 2.03 (2H, m), 1.20 (12H, m).
Compound 82.
1
yield 79 (52.8 mg, 0.0558 mmol, 72%, colorless oil). H NMR
(CDCl3): δ 7.29 (20H, m), 5.14-4.96 (6H, m), 4.82 (1H, m), 4.57
(2H, m), 4.43 (2H, m), 4.17 (1H, m), 4.07 (3H, m), 3.71 (2H, m),
2.90 (3H, m), 2.25 (2H, m), 1.55 (2H, m), 1.23 (28H, m), 0.86 (3H, t,
J=6.8 Hz). 13C NMR (CDCl3): δ 173.40, 167.99, 167.95, 156.55,
137.60, 136.27, 136.03, 135.49, 135.09, 134.91, 128.51, 128.47,
128.43, 128.39, 128.26, 128.22, 128.10, 128.04, 127.98, 127.95,
127.83, 127.78, 127.73, 77.20, 75.06, 74.99, 72.10, 69.58, 67.62,
67.58, 67.25, 66.41, 64.78, 62.24, 59.95, 34.06, 31.90, 29.68, 29.64,
29.60, 29.46, 29.34, 29.26, 29.12, 24.83, 22.67, 14.11. 31P NMR
(CDCl3): δ -0.51, -0.55, -0.65, -0.71. HRMS (ESI, [M þ
Na]þ): Calcd for C54H74NNaO11P: 966.4897. Found: 966.4891.
Compound 14.
Following the general procedure B, 43 (108.1 mg, 0.357 mmol),
81 (176.0 mg, 0.297 mmol), 1H-tetrazole (62.4 mg, 0.891 mmol),
TBHP (0.24 mL, 1.44 mmol), CH2Cl2 (2 mL), and THF (1.5 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 1:2) to yield 82 (96.1 mg, 0.121 mmol, 41%, colorless oil).
1H NMR (CDCl3): δ 7.27 (20H, m), 6.76 (4H, m), 5.12 (4H, m),
5.06-4.94 (5H, m), 4.62 (3H, m), 4.26 (1H, m), 4.11 (1H, m),
3.92 (2H, m), 3.84 (1H, m), 3.73 (3H, s), 3.66 (1H, m), 3.52 (1H,
m), 2.46 (1H, m), 2.25 (1H, m). HRMS (ESI, [M þ Na]þ): Calcd
for C44H46NNaO11P: 818.2706. Found: 818.2705.
Compound 83.
Following the general procedure L, 79 (27.6 mg, 0.0292 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to 7:2:1) to yield 14 (3.2 mg, 0.0059 mmol, 20%, white
powder). 1H NMR (CDCl3: CD3CO2D=4:1): δ 4.40-3.85 (6H,
m), 3.65 (1H, m), 3.34 (1H, m), 2.95-2.70 (3H, m), 2.25 (2H, m),
1.52 (2H, m), 1.17 (28H, m), 0.78 (3H, t, J=6.8 Hz). HRMS
(ESI, [M - H]-): Calcd for C25H49NO9P: 538.3145. Found:
538.3108. mp 156.5-157.0 ꢀC.
Following the general procedure K, 82 (85.3 mg, 0.107 mmol), CAN
(146.9 mg, 0.268 mmol), and CH3CN-H2O (2 mL) were used. The
crude mixture was chromatographed (EtOAc/hexane 1:1 to 4:1) to
yield the intermediate alcohol (45.8 mg, 0.0664 mmol, 62%, brown
oil). The obtained alcohol (45.8 mg, 0.0664 mmol) was acylated with
stearoyl chloride (24.2 mg, 0.0797 mmol) in CH2Cl2 (5 mL) in the
presence of DMAP (16.2 mg, 0.133 mmol). The crude mixture was
chromatographed (EtOAc/hexane 1:3) to yield 83 (59.3 mg, 0.0620
mmol, 93%, colorless oil). 1H NMR (CDCl3): δ 7.25 (20H, m), 5.14
(2H, m), 5.02 (2H, m), 4.93 (1H, m), 4.55 (3H, m), 4.17 (1H, m), 4.06
(3H, m), 3.69 (2H, m), 3,52 (1H, m), 2.25 (2H, m), 2.05 (2H, m), 1.55
(2H, m), 1.23 (28H, m), 0.86 (3H, t, J=6.8 Hz). 13CNMR(CDCl3):δ
173.38, 169.11, 168.98, 154.05, 137.52, 136.34, 136.21, 135.15, 128.72,
128.60, 128.47, 128.40, 128.17, 128.06, 128.01, 127.97, 127.88, 127.78,
80.16, 79.17, 74.91, 72.10, 69.81, 69.76, 67.41, 67.28, 66.17, 66.52,
66.05, 62.14, 44.52, 44.19, 34.05, 31.90, 29.67, 29.63, 29.60, 29.45,
29.34, 29.26, 29.12, 24.83, 22.67, 14.11. 31P NMR (CDCl3): δ -1.41,
-1.45, -1.54. HRMS (ESI, [M þ Na]þ): Calcd for C55H74-
NNaO11P: 978.4897. Found: 978.4890.
Synthesis of Compound 15-17 (Scheme 6). Synthesis of
Compound 15. Compound 80.
Following the general procedure E, trans-3-hydroxy-L-proline
(265.8 mg, 2.03 mmol), benzyl chloroformate (409.0 mg, 2.40
mmol), saturated aqueous NaHCO3 (10 mL), and THF (10 mL)
were used. The crude mixture was chromatographed (CHCl3/
MeOH 9:1 to 8:2) to yield N-Z-trans-3-hydroxy-L-proline (594.4
mg, 2.24 mmol, quantitative yield, colorless oil). The following
benzylation was carried out in accordance with the general proce-
dure F by using the intermediate alcohol (541.2 mg, 2.040 mmol),

5858 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Iwashita et al.
Compound 15.
were used. The crude mixture was chromatographed (EtOAc/
hexane 1:2) to yield 86 (70.7 mg, 0.089 mmol, 36%, colorless oil).
1H NMR (CDCl3): δ 7.30 (20H, m), 6.76 (4H, m), 5.20-4.94
(6H, m), 4.87 (1H, m), 4.64 (2H, m), 4.42 (1H, m) 4.24 (1H, m),
4.13 (1H, m), 3.92 (2H, m), 3.87 (1H, m), 3.78-3.67 (4H, m),
3.56 (1H, m), 2.41 (1H, m), 1.98 (1H, m). HRMS (ESI, [M þ
Na]þ): Calcd for C44H46NNaO11P: 818.2706. Found: 818.2707.
Compound 87.
Following the general procedure L, 83 (30.2 mg, 0.0316 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to 7:2:1) to yield 15 (3.0 mg, 0.00540 mmol, 17%, white
powder). 1H NMR (CDCl3/CD3CO2D 4:1): δ 5.22 (1H, m), 4.98
(1H, m), 4.09 (5H, m), 3.63-3.34 (3H, m), 3.08 (1H, m), 2.25
(2H, m), 1.53 (2H, m), 1.17 (28H, m), 0.78 (3H, t, J=6.8 Hz).
HRMS (ESI, [M - H]-): Calcd for C26H49NO9P: 550.3145.
Found: 550.3111. mp 150.5-151.0 ꢀC.
Following the general procedure K, 86 (88.4 mg, 0.111 mmol),
CAN (152.2 mg, 0.278 mmol), and CH3CN-H2O (2 mL) were
used. The crude mixture was chromatographed (EtOAc/hexane
1:1 to 4:1) to yield the intermediate alcohol. The obtained alcohol
was acylated with stearoyl chloride (43.0 mg, 0.142 mmol) in
CH2Cl2 (5 mL) in the presence of DMAP (40.7 mg, 0.333 mmol).
The crude mixture was chromatographed (EtOAc/hexane 1:3) to
yield 87 (62.2 mg, 0.0650 mmol, 59% (2 steps), colorless oil). 1H
NMR (CDCl3): δ 7.29 (20H, m), 5.20-4.94 (6H, m), 4.88 (1H, m),
4.57 (2H, m), 4.44 (1H, m), 4.18 (1H, m), 4.08 (3H, m), 3.65 (2H,
m), 3,58 (1H, m), 2.42 (1H, m), 2.25 (2H, m), 2.01 (1H, m), 1.55
(2H, m), 1.23 (28H, m), 0.86 (3H, t, J = 7.0 Hz). 13C NMR
(CDCl3): δ 173.39, 171.87, 171.65, 154.57, 153.99, 137.53, 136.25,
136.11, 135.39, 135.17, 128.74, 128.64, 128.55, 128.47, 128.41,
128.31, 128.17, 128.11, 128.07, 128.01, 127.90, 127.86, 127.84,
127.80, 127.78, 77.20, 76.28, 75.76, 75.71, 75.64, 75.59, 75.71,
75.64, 75.59, 75.09, 75.04, 74.96, 72.13, 69.76, 69.70, 67.34, 67.07,
66.96, 66.93, 66.46, 66.41, 62.14, 57.69, 57.42, 57.38, 53.60, 53.53,
53.46, 53.04, 37.84, 37.79, 36.78, 34.06, 31.89, 29.67, 29.63, 29.59,
29.45, 29.33, 29.25, 29.11, 24.83, 22.66, 14.09. 31P NMR (CDCl3):
δ -1.20. HRMS (ESI, [M þ Na]þ) Calcd for C55H74NNaO11P:
978.4897. Found: 978.4920.
Synthesis of Compound 16. Compound 84.
Following the general procedure E, trans-4-hydroxy-L-proline
(1.40 g, 10.7 mmol), benzyl chloroformate (2.05 g, 20.9 mmol),
saturated aqueous NaHCO3 (30 mL), and THF (60 mL) were
used. The crude mixture was chromatographed (CHCl3/MeOH
1:0 to 9:1) to yield N-Z-trans-4-hydroxy-L-proline (3.41 g,
12.9 mmol, quantitative yield, colorless oil). The following benzy-
lation was carried out in accordance with the general procedure
F by using the intermediate alcohol (789.5 mg, 2.977 mmol), benzyl
bromide (619.2 mg, 3.572 mmol), triethylamine (2 mL, 14.67
mmol), and THF (10 mL). The crude mixture was chromato-
graphed (EtOAc/hexane 1:2 to 2:1) to yield 84 (768.3 mg, 2.162
1
mmol, 94% (2 steps), colorless oil). H NMR (CDCl3): δ 7.32
(10H, m), 5.14 (2H, m), 5.03 (2H, m), 4.56 (1H, m), 4.49 (1H, m),
3.70-3.50 (2H, m), 2.29 (1H, m), 2.08 (1H, m). HRMS (ESI, [M þ
Na]þ): Calcd for C20H21NNaO5: 378.1317. Found: 378.1319.
Compound 85.
Compound 16.
Following the general procedure L, 87 (31.5 mg, 0.0329 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to 7:2:1) to yield 16 (12.7 mg, 0.0230 mmol, 70%, white
powder). 1H NMR (CDCl3/CD3CO2D 4:1): δ 5.06 (1H, m),
4.67-4.37 (1H, m), 4.05 (2H, m), 3.97-3.80 (3H, m), 3.48 (2H,
m), 3.04 (1H, m), 2.70 (1H, m), 2.25 (2H, m), 1.52(2H, m), 1.17
(28H, m), 0.78 (3H, t, J=6.8 Hz). HRMS (ESI, [M - H]-): Calcd
for C26H49NO9P: 550.3145. Found: 550.3135. mp 188.0-188.5 ꢀC.
Synthesis of Compound 17. Compound 88.
Following the general procedure A, 84 (204.9 mg, 0.577 mmol),
27 (174.7 mg, 0.577 mmol), 1H-tetrazole (40.4 mg, 0.577 mmol),
CH2Cl2 (5 mL), and THF (1.2 mL) were used. The crude mixture
was chromatographed (EtOAc/hexane/Et3N 100:0:3 to 20:80:3) to
1
yield 85 (167.0 mg, 0.282 mmol, 49%, colorless oil). H NMR
(CD2Cl2): δ 7.32 (15H, m), 5.15-4.45 (8H, m), 3.66 (2H, m), 3.52
(1H, m), 3.23 (1H, m), 2.40 (1H, m), 2.09 (2H, m), 1.20 (12H, m).
Compound 86.
Following the general procedure E, cis-4-hydroxy-L-proline (164.7
mg, 1.26 mmol), benzyl chloroformate (257.1 mg, 1.51 mmol), satd
NaHCO3 (5 mL), and THF (5 mL) were used. The crude mixture
was chromatographed (CHCl3/MeOH 1:0 to 9:1) to yield N-Z-cis-
4-hydroxy-L-proline (316.1 mg, 1.19 mmol, 95%, colorless oil). The
Following the general procedure B, 43 (89.3 mg, 0.295 mmol),
85 (145.5 mg, 0.246 mmol), 1H-tetrazole (51.7 mg, 0.738 mmol),
TBHP (0.12 mL, 0.72 mmol), CH2Cl2 (2 mL), and THF (1.5 mL)

Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5859
following benzylation was carried out in accordance with the
general procedure F by using the intermediate alcohol (316.1 mg,
1.19 mmol), benzyl bromide (305.6 mg, 1.79 mmol), triethylamine
(0.60 mL, 3.58 mmol), and THF (10 mL). The crude mixture
was chromatographed (EtOAc/hexane 2:3) to yield 88 (321.5 mg,
0.905 mmol, 72% (2 steps), colorless oil). 1H NMR (CDCl3): δ 7.32
(10H, m), 5.28-4.99 (6H, m), 4.66 (1H, m), 4.66 (1H, m), 3.73 (1H,
m), 3.63 (1H, m), 2.34 (2H, m), 2.11 (2H, m). HRMS (ESI, [M þ
Na]þ): Calcd for C20H21NNaO5: 378.1317. Found: 378.1319.
Compound 89.
77.21, 76.31, 76.26, 76.21, 75.40, 75.35, 75.31, 75.12, 75.05, 72.12,
72.07, 69.58, 69.53, 69.48, 67.32, 67.29, 67.23, 66.96, 66.88, 66.46,
66.40, 66.35, 66.29, 65.81, 62.23, 57.69, 57.44, 53.49, 53.44, 53.39,
53.11, 53.05, 53.00, 37.62, 37.58, 36.67, 36.61, 34.05, 31.88, 30.06,
29.66, 29.62, 29.59, 29.44, 29.32, 29.25, 29.11, 24.83, 15.24, 14.09.
31P NMR (CDCl3): δ -1.51, -1.58, -1.65. HRMS (ESI, [M þ
Na]þ): Calcd for C55H74NNaO11P: 978.4897. Found: 978.4897.
Compound 17.
Following the general procedure L, 91 (32.2 mg, 0.0336 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to 8:1:1
to 7:2:1) to yield 17 (13.1 mg, 0.0237 mmol, 71%, white powder).
1H NMR (CDCl3/CD3CO2D 4:1): δ 5.03 (1H, m), 4.64 (1H, m),
4.23(1H,m),4.05(2H,m),3.96(2H, m),3.87(2H, m),3.32(1H, m),
3.00 (1H, m), 2.55 (1H, m), 2.24 (2H, m), 1.52(2H, m), 1.16 (28H,
m), 0.78 (3H, t, J=6.8 Hz). HRMS (ESI, [M - H]-): Calcd for
C26H49NO9P: 550.3145. Found: 550.3096. mp 198.5-199.0 ꢀC.
Synthesis of 2-Deoxy-lysoPT Derivatives 18 and 19
(Scheme 7). Synthesis of Compound 18. Compound 92.
Following the general procedure A, 88 (217.5 mg, 0.612 mmol),
27 (198.0 mg, 0.600 mmol), 1H-tetrazole (42.1 mg, 0.600 mmol),
CH2Cl2 (5 mL), and THF (1.2 mL) were used. The crude mixture
was chromatographed (EtOAc/hexane/Et3N 100:0:3 to 20:80:3)
to yield 89 (235.5 mg, 0.398 mmol, 66%, colorless oil). 1H NMR
(CD2Cl2): δ 7.32 (15H, m), 5.10 (5H, m), 4.64 (2H, m), 4.48
(2H, m), 3.73 (1H, m), 3.58 (2H, m), 2.38 (2H, m), 1.20 (12H, m).
Compound 90.
Following the general procedure B, 24 (125.5 mg, 0.366 mmol),
65 (175.2 mg, 0.302 mmol), 1H-tetrazole (63.1 mg, 0.900 mmol),
TBHP (0.15 mL, 0.900 mmol), CH2Cl2 (2 mL), and THF (2 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 1:3) to yield 92 (193.1 mg, 0.230 mmol, 76%, colorless
oil). 1H NMR (CDCl3): δ 7.31 (15H, m), 5.56 (1H, m),
5.22-4.87 (7H, m), 4.46 (1H, m), 4.08 (2H, m), 3.98 (2H, m),
2.23 (2H, m), 1.86 (2H, m), 1.55 (2H, m), 1.38 (3/2H, d, J =
6.4 Hz), 1.33 (3/2H, d, J=6.4 Hz), 1.23 (28H, m), 0.86 (3H, t, J=
6.8 Hz). 13C NMR (CDCl3): δ 173.55, 175.51, 169.25, 156.41,
135.92, 135.52, 135.44, 134.85, 134.83, 128.63, 128.52, 128.48,
128.41, 128.38, 128.34, 128.29, 128.23, 128.11, 127.96, 127.90,
127.76, 75.24, 69.31, 67.58, 67.16, 65.70, 64.45, 59.95, 58.46,
58.40, 34.03, 31.79, 29.57, 29.53, 29.49, 29.35, 29.30, 29.23,
29.14, 29.02, 24.76, 22.57, 18.40, 18.31, 15,15, 14.10. 31P NMR
(CDCl3): δ -1.26, -1.35. HRMS (ESI, [M þ Na]þ): Calcd for
C47H68NNaO10P: 860.4479. Found: 860.4469.
Following the general procedure B, 43 (132.3 mg, 0.437 mmol),
89 (215.4 mg, 0.364 mmol), 1H-tetrazole (76.5 mg, 1.092 mmol),
TBHP (0.18 mL, 1.08 mmol), CH2Cl2 (2 mL), and THF (2 mL)
were used. The crude mixture was chromatographed (EtOAc/
hexane 2:3 to 1:1) to yield 90 (169.1 mg, 0.212 mmol, 58%,
colorless oil). 1H NMR (CDCl3): δ 7.30 (20H, m), 6.77 (4H, m),
5.17-4.89 (7H, m), 4.64 (2H, m), 4.53-4.42 (1H, m), 4.22 (1H,
m), 4.10 (1H, m), 3.93 (2H, m), 3.85 (1H, m), 3.73-3.57 (5H, m),
2.41 (1H, m), 2.27 (1H, m). HRMS (ESI, [M þ Na]þ): Calcd for
C44H46NNaO11P: 818.2706. Found: 818.2705.
Compound 91.
Compound 18 (2-Deoxy-lysoPT).
Following the general procedure K, 90 (116.7 mg, 0.147 mmol),
CAN (201.0 mg, 0.367 mmol), and CH3CN-H2O (2 mL) were
used. The crude mixture was chromatographed (EtOAc/hexane
1:1 to 4:1) to yield the intermediate alcohol (90.8 mg, 0.132 mmol,
90%, brown oil). The alcohol (90.8 mg, 0.132 mmol) was acylated
with stearoyl chloride (47.9 mg, 0.158 mmol) in CH2Cl2 (5 mL) in
the presence of DMAP (32.2 mg, 0.263 mmol). The crude mixture
was chromatographed (EtOAc/hexane 1:2) to yield 91 (92.7 mg,
0.097 mmol, 73%, colorless oil). 1H NMR (CDCl3): δ 7.30 (20H,
m), 5.18-4.87 (7H, m), 4.57 (2H, m), 4.42 (1H, m), 4.17 (1H, m),
4.08 (2H, m), 3.95 (1H, m), 3.73 (3H, m), 2.38 (2H, m), 2.25 (2H,
m), 1.55 (2H, m), 1.23 (28H, m), 0.86 (3H, t, J=6.8 Hz). 13C NMR
(CDCl3): δ 173.37, 173.08, 171.01, 171.08, 170.75, 154.49, 154.06,
137.63, 137.60, 137.56, 136.26, 136.21, 135.50, 135.43, 135.38,
128.66, 128.61, 128.55, 128.51, 128.46, 128.38, 128.21, 128.13,
128.07, 128.01, 127.97, 127.94, 127.86, 127.83, 127.81, 127.74,
Following the general procedure L, 92 (47.6 mg, 0.0568 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1) and the product was washed with MeOH to yield 18
(8.6 mg, 0.0165 mmol, 29%, white powder). 1H NMR (CDCl3/
CD3CO2D 4:1): δ 4.88 (1H, m), 4.09 (3H, m), 3.99 (2H, m), 2.22
(2H, m), 1.90 (2H, m), 1.50 (2H, m), 1.17 (31H, m), 0.78 (3H, t,
J=6.6 Hz). HRMS (ESI, [M - H]-): Calcd for C25H49NO8P:
522.3196. Found: 522.3167. Anal. Calcd for C25H50NO8P þ
4/3CF3CO2H: C, 49.18; H, 7.66; N, 2.07. Found: C, 49.24; H,
7.99; N, 1.86. mp 177.5-178.0 ꢀC.

5860 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Iwashita et al.
Synthesis of Compound 19. Compound 93.
ester (2.51 g, 7.31 mmol, 50%, white solid). 1H NMR (CDCl3): δ
7.33 (10H, m), 5.52 (1H, m), 5.19 (2H, m), 5.11 (2H, m), 4.36
(2H, m), 1.76 (1H, brs), 1.22 (3H, d, J=6.4 Hz).
Compound 65-D.
To a solution of 1,3-propane diol (3.066 g, 40.3 mmol) and pyridine
(1.0 mL, 12 mmol) in CH2Cl2 (8 mL), a solution of palmitoyl
chloride (2.744 g, 9.99 mmol) in CH2Cl2 (8 mL) was added dropwise
and the whole was stirred for 18 h at room temperature. After
quenching with 3N aqueous HCl, the separated organic layer was
washed with 3N aqueous HCl and brine and the organic layer was
dried over Na2SO4. The organic solvent was evaporated, and the
residue was chromatographed (EtOAc: hexane=1: 3) to yield 93
Following the general procedure B, 27 (2.032 g, 6.00 mmol), N-
Z-D-threonine benzyl ester (2.060 g, 6.00 mmol), 1H-tetrazole
(420 mg, 6.00 mmol), CH2Cl2 (48 mL), and THF (12 mL) were
used. The mixture was chromatographed (hexane:EtOAc:Et3-
N=35:4:1) to yield 65-D (2.785 g, 4.80 mmol, 80%, colorless
oil). 1H NMR (CD2Cl2): δ 7.34 (15H, m), 5.61 (1H, d, J =
9.3 Hz), 5.51 (1H, d, J=9.3 Hz), 5.12 (4H, m), 4.71 (1H, m), 4.60
(2H, m), 4.36 (1H, m), 3.60 (2H, m), 1.31 (3H, m), 1.17 (12H, m).
Compound 94-D.
1
(1.394 g, 4.44 mmol, 44%, colorelss solid). H NMR (CDCl3): δ
4.22 (2H, t, J=6.1 Hz), 3.67 (2H, m), 2.29 (2H, t, J=7.6 Hz), 1.85
(2H, m), 1.59 (2H, m), 1.23 (24H, m), 0.86 (3H, t, J=6.8 Hz).
Compound 94.
Following the general procedure C, 93 (360.0 mg, 1.15 mmol), 65
(585.7 mg, 1.01 mmol), 1H-tetrazole (192.5 mg, 2.75 mmol), TBHP
(0.45 mL, 2.70 mmol), CH2Cl2 (6mL), andTHF(6mL) were used.
The crude mixture was chromatographed (EtOAc: hexane=1: 2)
to give 94 (502.5 mg, 0.621 mmol, 61%, colorless oil). 1H NMR
(CDCl3): δ 7.31 (15H, m), 5.57 (1H, m), 5.22-4.90 (7H, m), 4.47
(1H, m), 4.09 (2H, m), 3.97 (2H, m), 2.23 (2H, t, J=7.5 Hz), 1.87
(2H, m), 1.55 (2H, m), 1.39 (3/2H, d, J=6.4 Hz), 1.33 (3/2H, d, J=
6.4 Hz), 1.23 (24H, m), 0.86 (3H, t, J=6.8 Hz).
Following the general procedure C, 93 (158.7 mg, 0.505 mmol),
65-D (303.3 mg, 0.522 mmol), 1H-tetrazole (70.0 mg, 1.00 mmol),
TBHP (0.24 mL, 1.44 mmol), CH2Cl2 (3 mL), and THF (3 mL)
were used. The crude mixture was chromatographed (EtOAc:
hexane=1:2) to give 94-D (336.3 mg, 0.416 mmol, 82%, colorless
oil). 1H NMR (CDCl3): δ 7.31 (15H, m), 5.57 (1H, m), 5.22-4.91
(7H, m), 4.47 (1H, m), 4.09 (2H, m), 3.97 (2H, m), 2.23 (2H, m),
1.86 (2H, m), 1.55 (2H, m), 1.39 (3H, d, J=6.4 Hz), 1.33 (3H, d,
J=6.4 Hz), 1.25 (24H, m), 0.86 (3H, t, J=6.8 Hz).
Compound 19.
Compound 19-D.
A solution of 94 (223.5 mg, 0.276 mmol) in MeOH (16 mL) and
AcOH (4 mL) was hydrogenataed with Pd-C (20.0 mg) for 1
day at rt. After filtration, the solvent was evaporated and the
residue was chromatographed (CHCl3:MeOH:AcOH=9:0:1 f
8:1:1) to yield 19 (44.0 mg, 0.0888 mmol, 32%, colorless
powder). 1H NMR (CDCl3:CD3COOD=4:1): δ 4.83 (1H, m),
4.08 (2H, m), 3.86 (3H, m), 2.21 (2H, m), 1.86 (2H, m), 1.52 (2H,
m), 1.33 (3H, m), 1.18 (24H, m), 0.79 (3H, t, J=6.8 Hz). HRMS
(ESI, [M - H]-): Calcd for C23H45NO8P: 494.2883. Found:
494.2863.
Following the general procedure D, 94-D (98.4 mg, 0.122
mmol), Pd-C (5.0 mg), and MeOH-AcOH (10 mL) were used.
The crude mixture was chromatographed (CHCl3:MeOH:
AcOH = 6:3:1), and the product was precipitated by using
1
MeOH to yield 19-D (17.9 mg, 0.0361 mmol 30%). H NMR
(CDCl3:CD3CO2D=4:1): δ 4.76 (1H, m), 4.08 (2H, m), 3.84
(3H, m), 2.21 (2H, m), 1.84 (2H, m), 1.52 (2H, m), 1.34 (3H, m),
1.18 (24H, m), 0.79 (3H, t, J=6.8 Hz). HRMS (ESI, [M - H]-):
Calcd for C23H45NO8P: 494.2883. Found: 494.2912.
Synthesis of Compound 19-D. N-Z-D-Threonine. D-Threonine
(2.027 g, 17.0 mmol) was dissolved in saturated aqueous NaHCO3
(100 mL) and THF (50 mL) and the whole was cooled to 0 ꢀC.
To this solution, a solution of benzyl chloroformate (3.481 g, 20.4
mmol) in THF (50 mL) was added at 0 ꢀC and the whole was stirred
for 1.5 h at 0 ꢀC. After quenching with 3N aqueous HCl, the
separated organic layer was washed with 3N aqueous HCl and brine
and dried over Na2SO4. The organic solvent was evaporated, and
the residue was chromatographed (CHCl3:MeOH=1:0 f 9:1) to
give N-Z-D-threonine (3.671 g, 85%, pale-yellow oil). H NMR
(CDCl3): δ 7.30 (m, 5H), 5.93 (1H, d, J=8.8 Hz), 4.37 (1H, m), 4.31
(1H, d, J=8.6 Hz), 1.18 (3H, d, J=6.2 Hz).
N-Z-D-Threonine Benzyl Ester. Following the general proce-
dure F, N-Z-D-threonine (3.661 g, 14.5 mmol), TBAI (1.041 g,
2.00 mmol), triethylamine (5.80 mL), benzyl bromide (2.10 mL),
and THF (71 mL) were used. The crude mixture was chromato-
graphed (EtOAc:hexane=1:1) to yield N-Z-D-threonine benzyl
Synthesis of LysoPT Analogues 20 (C-12) and 21 (C-16)
(Scheme 8). Synthesis of Compound 20 (LysoPT C-12). Compound 95.
1
Following the general procedure K, 67 (250.1 mg, 0.319 mmol),
CAN (441.4 mg, 0.805 mmol), and CH3CN-H2O (3 mL) were used.
The crude mixture was chromatographed (EtOAc/hexane 1:1 to 4:1)
to yield the intermediate alcohol (154.6 mg, 0.228 mmol, 71%, brown
oil). The obtained alcohol (219.1 mg, 0.323 mmol) was acylated with
lauroyl chloride (84.7 mg, 0.387 mmol) in CH2Cl2 (10 mL) in the
presence of DMAP (118.4 mg, 0.969 mmol). The crude mixture was

Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5861
chromatographed (EtOAc/hexane 1:3 to 2:3) to yield 95 (154.6 mg,
0.180 mmol, 56%, colorless oil). 1H NMR (CDCl3): δ 7.31 (20H, m),
5.57 (1H, m), 5.20-4.89 (7H, m), 4.56 (2H, m), 4.48 (1H, m), 4.19
(1H, m), 4.08-3.96 (3H, m), 3.70 (1H, m), 2.26, (2H, m), 1.55 (2H,
m), 1.36 (3/2H, d, J=6.4Hz),1.31(3/2H, d, J=6.4Hz),1.23(16H,m),
0.85 (3H, t, J=7.0 Hz). 13C NMR (CDCl3): δ 173.28, 169.24, 169.21,
156.39, 137.50, 137.46, 135.93, 135.91, 135.39, 134.86, 134.82, 128.51,
128.46, 128.40, 128.33, 128.27, 128.23, 128.10, 127.95, 127.81, 127.76,
127.73, 127.70, 127.66, 75.42, 75.37, 75.32, 74.92, 74.84, 74.76, 71.98,
71.87, 69.43, 69.37, 69.33, 67.60, 67.56, 67.17, 67.15, 66.24, 66.18,
66.12, 65.69, 62.12, 58.44, 58.38, 33.93, 31.76, 29.46, 29.32, 29.19,
29.13, 28.98, 24.71, 22.54, 18.39, 18.32, 15.15, 14.00. 31P NMR
(CDCl3): δ -1.32, -1.38. HRMS (ESI, [M þ Na]þ): Calcd for
C48H62NNaO11P: 882.3958. Found: 882.3957.
mixture was chromatographed (CHCl3/MeOH/AcOH 9:0:1 to
8:1:1 to 7:2:1) and the product was washed with MeOH to yield
21 (12.8 mg, 0.0250 mmol, 52%, white powder). 1H NMR
(CDCl3/CD3CO2D 4:1): δ 4.80 (1H, m), 4.14-3.85 (6H, m),
2.24 (2H, m), 1.49 (2H, m), 1.17 (27H, m), 0.78 (3H, t, J =
6.8 Hz). HRMS (ESI, [M - H]-): Calcd for C23H45NO9P:
510.2832. Found: 510.2839. mp 173.0-173.5 ꢀC.
Synthesis of 22 (1-Deoxy-lysoPT) (Scheme 9). Compound 97.
Compound 20 (LysoPT-C12).
Following the general procedure G, (R)-1,2-propanediol (1.20 g,
15.74 mmol), TBAI (1.627 mg, 4.41 mmol), DIPEA (3.93 g,
5.30 mL, 30.43 mmol), 4,4-dimethoxy tritylchloride (5.59 g,
16.50 mmol), and CH2Cl2 (100 mL) were used. The crude mixture
was chromatographed (EtOAc:hexane=1:4f1:3) to yield 97 (5.98g,
1
15.79 mmol, quantitative yield, yellow oil). H NMR (CDCl3):
δ 7.45-7.19 (11H, m), 6.81 (4H, m), 3.96 (1H, m), 3.77 (3H, s),
3.61-3.37, 3.11-2.95 (3H, m), 1.15-1.08 (3H, m).
Compound 98.
Following the general procedure L, 95 (46.5 mg, 0.0541 mmol), Pd-C
(3.0mg),andMeOH-AcOH(5mL) wereused.Thecrudemixturewas
chromatographed (CHCl3/MeOH/AcOH 9:0:1 to 8:1:1 to 7:2:1) and
the product was washed with MeOH to yield 20 (15.8 mg, 0.0347
mmol, 64%, whitepowder).1HNMR(CDCl3/CD3CO2D4:1):δ4.90
(1H, m), 4.16-3.99 (6H, m), 2.25 (2H, m), 1.49(2H, m), 1.17 (19H, m),
0.78 (3H, t, J = 6.8 Hz). HRMS (ESI, [M - H]-): Calcd for
C19H37NO9P: 454.2206. Found: 454.2168. mp 164.5-165.0 ꢀC.
Synthesis of Compound 21 (LysoPT C-16). Compound 96.
To a solution of 97 (2.191 g, 5.79 mmol) and TBAI (641.4 mg, 1.736
mmol) in THF, NaH (55% in mineral oil, 631.4 mg, 14.47 mmol)
was added at 0 ꢀC and the whole was stirred for 10 min. To this
mixture, p-methoxybenzyl chloride (1.09 g, 6.946 mmol) was added,
and the whole was heated to 70 ꢀC and stirred for 16 h at 70 ꢀC.
The reaction was quenched with ice water, and the organic layer was
diluted with EtOAc, washed with brine, and dried over Na2SO4. The
organic solvent was evaporated, chromatographed to yield 98 (2.235
g, 4.483 mmol, 78%, yellow oil). 1H NMR (CDCl3): δ 7.45-7.13
(13H, m), 6.87 (4H, m), 4.59-4.38 (2H, m), 3.78 (9H, m), 3.57-
3.47, 3.20-2.97 (3H, m), 1.14 (3H, d, J=6.0 Hz)
Following the general procedure K, 67 (250.1 mg, 0.319 mmol),
CAN (441.4 mg, 0.805 mmol), and CH3CN-H2O (3 mL) were used.
The crude mixture was chromatographed (EtOAc/hexane 1:1 to 4:1)
to yield the intermediate alcohol (154.6 mg, 0.228 mmol, 71%, brown
oil). The obtained alcohol (219.1 mg, 0.323 mmol) was acylated with
palmitoyl chloride (106.4 mg, 0.387 mmol) in CH2Cl2 (10 mL) in the
presence of DMAP (118.4 mg, 0.969 mmol). The crude mixture was
chromatographed (EtOAc/hexane 1:3 to 2:3) to yield 96 (146.7 mg,
0.160 mmol, 50%, colorless oil). 1H NMR (CDCl3): δ 7.31 (20H, m),
5.56 (1H, m), 5.21-4.87 (7H, m), 4.57 (1H, m), 4.46 (1H, m), 4.19
(1H,m),4.08-3.94 (3H, m), 2.24 (3H, m), 1.55 (2H, m), 1.36 (3/2H, d,
J=6.4 Hz), 1.31 (3/2H, d, J=6.4 Hz), 1.26 (25H, m), 0.85 (3H, t, J=
7.0 Hz). 13C NMR (CDCl3): δ 173.42, 169.32, 156.48, 137.59, 137.55,
135.98, 135.48, 134.95, 134.91, 128.62, 128.57, 128.52, 128.45, 128.38,
128.22, 128.07, 127.91, 127.86, 127.82, 127.76, 77.20, 75.48, 75.02,
74.94, 74.86, 72.11, 72.00, 69.54, 69.49, 69.44, 67.72, 67.69, 67.30,
66.29, 62.24, 58.55, 58.47, 34.05, 31.89, 29.66, 29.62, 29.59, 29.44,
29.33, 29.25, 29.10, 24.81, 22.66, 18.51, 18.43, 15.24, 14.10. 31P NMR
(CDCl3): δ -1.24, -1.30. HRMS (ESI, [M þ Na]þ): Calcd for
C52H70NNaO11P: 938.4584. Found: 938.4595.
Compound 99.
To a solution of 98 (2.103 g, 4.218 mmol) in CH2Cl2-MeOH
(1:3, 10 mL), PPTS (212.1 mg, 0.844 mmol) was added and the
whole was stirred at rt for 1 h. The reaction was quenched with
triethylamine, the solvent was evaporated, and the residue was
chromatographed to yield 99 (726.5 mg, 3.702 mmol, 88%, color-
less oil). 1H NMR (CDCl3):δ 7.26 (1H, m), 7.24 (1H, m), 6.88 (1H,
m), 6.86 (1H, m), 4.57 (1H, m), 4.38 (1H, m), 3.79 (3H, s), 3.64 (1H,
m), 3.57 (1H, m), 3.47 (1H, m), 1.14 (3H, d, J=6.4 Hz).
Compound 100.
Compound 21.
Following the general procedure B, 99 (196.2 mg, 1.00 mmol),
28 (225.9 mg, 0.399 mmol), 1H-tetrazole (84.1 mg, 1.20 mmol),
TBHP (0.2 mL, 1.20 mmol), CH2Cl2 (2 mL), and THF (2.4 mL)
were used. The crude mixture was chromatographed (EtOAc:
hexane=1:2) to yield 100 (199.8 mg, 0.295 mmol, 74%, colorless
1
Following the general procedure L, 96 (44.1 mg, 0.0482 mmol),
Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used. The crude
oil). H NMR (CDCl3): δ 7.36-7.17 (15H, m), 6.80 (4H, m),
5.90 (1H, m), 5.18-5.08 (4H, m), 4.94 (2H, m), 4.56 (1H, m),

5862 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19
Iwashita et al.
4.43 (2H, m), 4.39 (1H, m), 4.26 (1H, m), 3.90 (2H, m), 3.75 (3H,
s), 3.63 (1H, m), 1.08 (3H, m).
Compound 101.
as the means ( SE for several replicate experiments on different
samples of pooled cells.
Lipid Extraction. Lipids were extracted from 200 μL of rat
sera using Extract Cartridges (Oasis HLB, Hydrophilic-
Lipophilic Balance, 30 mg, Waters). Extracted lipids were dried
and sonicated with 200 μL of 0.01% BSA-HBT in serial dilu-
tions.
Evaluation of Hypothermic Effect of LysoPS Analogues.
LysoPS analogues were suspended in PBS containing 0.1%
bovine serum albumin and were injected iv. Rectal temperatures
were measured with a rectal probe every 5 or 10 min for 60 min.
Plasma Histamine Level. Blood was drawn from lysoPS
analogue-injected mice 2 min after the injection. Histamine
levels were determined using an enzyme immunoassay kit
(IBL) according to the manufacturer’s directions.
To a solution of 100 (101.6 mg, 0.15 mmol) in CH2Cl2-
phosphate buffer (1:1, 2 mL), DDQ (85.1 mg, 0.375 mmol)
was added at 0 ꢀC and the whole was stirred for 1 h. The reaction
mixture was diluted with EtOAc, and the separated organic
solvent was washed with saturated aqueous NaHCO3 and brine
and dried over Na2SO4. The solvent was evaporated, and the
residue was chromatographed (EtOAc:hexane=1:1) to yield the
intermediate alcohol. To a solution of the obtained alcohol and
DMAP (61.1 mg, 0.500 mg) in CH2Cl2, a solution of stearoyl
chloride (54.5 mg, 0.18 mmol) in CH2Cl2 was added at 0 ꢀC and
the whole was stirred for 1 h. The solvent was evaporated and
the residue was chromatographed (EtOAc:hexane=1:3) to yield
101 (26.5 mg, 0.0326 mmol, 22%, colorless oil). 1H NMR
(CDCl3): δ 7.31 (15H, m), 5.85 (1H, m), 5.16 (2H, m), 5.09
(2H, m), 4.96 (3/2H, m), 4.58 (3/2H, m), 4.42 (1H, m), 4.27 (1H,
m), 4.08-3.84 (2H, m), 2.21 (2H, m), 1.57 (2H, m), 1.22-1.14
(31H, m), 0.86 (3H, t, J=6.8 Hz). 13C NMR (CDCl3): δ 173.40,
168.78, 155.85, 136.07, 135.52, 134.96, 128.77, 128.64, 128.55,
128.31, 128.24, 128.12, 128.02, 127.98, 127.92, 127.88, 77.20,
73.71, 69.51, 67.77, 67.21, 66.49, 66.42, 54.54, 34.33, 33.99,
31.94, 29.72, 29.68, 29.64, 29.49, 29.38, 29.29, 29.14, 24.86,
24.79, 22.71, 18.05, 16.01, 14.14. 31P NMR (CDCl3): δ -0.94,
-0.96, -1.71, -1.74. HRMS (ESI, [M þ Na] þ): Calcd for
C46H66NNaO10Pþ: 846.4322. Found: 846.4303.
GPR34 Stable Transformants and cAMP, MAP Kinase, and
Calcium Assays. CHO-K1 cells were transfected with flag-
tagged rat/mouse GPR34-pCAGGS or empty vector using
TransIT-CHO reagent (Minus). The transfected cells were
treated with 750 μg/mL G418 (Calbiochem) and cells that
survived the treatment were subjected to immunomagnetic
positive selection (MACS, Miltenyi Biotech) using antiflag
antibody. For cAMP assay, cells were cultured overnight and
pretreated with 0.5 mM 3-isobutyl-1-methylxanthine (Wako).
After 20 min, cells were costimulated with various concentra-
tions of lysoPS analogues in the presence of 25 μM forskolin for
30 min at 37 ꢀC and the accumulated cAMP concentrations were
measured using a cAMP-Screen System (Applied Biosystems).
Intracellular Ca2þ concentration was determined using a CAF-
110 spectrofluorometer (JASCO) by stimulating Fura-2-loaded
cells with lysoPS analogues and expressed as the ratio of
emission fluorescence at 500 nm upon excitation at 340 and
380 nm. MAP kinase activation was evaluated by Western
blotting analyses using antibodies for phospho-p42/p44 MAP
kinase and p42/p44 MAP kinase (Cell Signaling Technology).
Serum-starved cells were stimulated with lysoPS analogues for
5 min at 37 ꢀC, and after the reactions were stopped by rapid
cooling on ice, the cells were lysed with lysis buffer (10 mM Tris,
250 mM sucrose, 1 mM EDTA, 0.5% NP-40, 50 mM NaF,
1 mM Na3VO4, 10 μg/mL aprotinin, 10 μg/mL leupeptin, 1 mM
PMSF) and an aliquot of protein (6 μg) was subjected to
Western blot analysis.
Compound 22 (1-Deoxy-lysoPT).
Expression Analysis. Mouse peritoneal mast cells were pre-
pared from male C57BL/6 mice. Crude mast cells were purified
with Percoll gradient as previously described. For preparation
of bone marrow-derived mast cells, bone marrow cells from
male C57BL/6 mice were cultured for 4- 6 weeks in RPMI 1640
containing recombinant mouse IL-6. The amount of GPR34
RNA were quantified using 7300 Real Time PCR System
(Applied Biosystems). The sequence of the primers for GPR34
were 50-ATGTGGCTGTTGCAGACCTTCTA-30 and 50-AC-
ACCTAGTGTCCACTTGTTTTGG-30. The copy numbers for
GPR34 were normalized by those of glyceraldehydes-3-phos-
phate dehydrogenase (GAPDH).
Following the general procedure L, 101 (29.4 mg, 0.0357
mmol), Pd-C (3.0 mg), and MeOH-AcOH (5 mL) were used.
The crude mixture was chromatographed (CHCl3:MeOH:
AcOH=9:0:1 f 8:1:1 f 7:2:1), and the product was precipitated
by using MeOH to yield 22 (12.0 mg, 0.0235 mmol, 66%, white
1
powder). H NMR (CDCl3:CD3CO2D=4:1): δ 4.41 (3H, m),
4.20 (1H, m), 4.00 (1H, m), 3.82 (1H, m), 2.24 (2H, m), 1.53(2H,
m), 1.17 (31H, m), 0.79 (3H, t, J=6.6 Hz). HRMS (ESI, [M -
H]-): Calcd for C24H47NO8P-: 508.3039. Found: 508.3026.
Anal. Calcd for C24H48NO8P 6/7CF3CO2H: C, 50.85; H, 8.11;
3
Statistical Analysis. Student’s t test was used for comparisons
between groups. All statistical analyses were performed by using
EXCEL. A P value of 0.05 or less was considered to indicate a
significant difference.
N, 2.31. Found: C, 50.74; H, 8.44; N, 2.13. mp 152.5-153.0 ꢀC.
Mast Cell Degranulation in Vitro. Mast cells from the perito-
neal cavity of mice and rats were prepared essentially as
described previously.8 The mast cells were suspended at a cell
density of 5 ꢀ 104/mL (in 0.2 mL) in HEPES-buffered Tyrode
(HBT) solution and stimulated with each lysoPS analogue in the
presence of concanavalin A (100 μg/mL for rat and 10 μg/mL for
mouse), which is known to cross-link the FcεRI receptor, for
15 min at 37 ꢀC. In IgE/Ag-induced degranulation, rat perito-
neal mast cells (RPMCs) were passively sensitized with 10 μg/
mL anti-DNP IgE for 30 min at 37 ꢀC. The cells were washed
and stimulated with each lysoPS analogue in the presence of
100 ng/mL DNP-As for 15 min at 37 ꢀC. The histamine content
in the supernatant was determined by the fluorometric assay of
Shore et al.15 Histamine release was calculated as a percentage of
the total cell content. Values for histamine release are presented
Acknowledgment. This research was supported by grants
from the National Institute of Biomedical Innovation, PRE-
STO (Japan Science and Technology Corporation), the 21st
Century Center of Excellence Program, and the Ministry of
Education, Science, Sports, and Culture of Japan to J.A.,
T.O., and H.A.
Supporting Information Available: Effect of lysoPS analogues
on mast cell degranulation; LysoPT is not cytotoxic; LysoPT
has its targets on mast cell membrane. Measurement of LDH

Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 19 5863
release. Withdrawal of lysoPT from mast cell membrane with
buffer containing BSA. This material is available free of charge
via the Internet at http://pubs.acs.org.
through production of 2-acyl-1-lysophosphatidylserine. J. Biol.
Chem. 2001, 276, 29664–29670.
(9) Kawamoto, K.; Aoki, J.; Tanaka, A.; Itakura, A.; Hosono, H.;
Arai, H.; Kiso, Y.; Matsuda, H. Nerve growth factor activates mast
cells through the collaborative interaction with lysophosphatidyl-
serine expressed on the membrane surface of activated platelets.
J. Immunol. 2002, 168, 6412–6419.
(10) Sato, T.; Aoki, J.; Nagai, Y.; Dohmae, N.; Takio, K.; Doi, T.; Arai,
H.; Inoue, K. Serine phospholipid-specific phospholipase A that is
secreted from activated platelets. A new member of the lipase
family. J. Biol. Chem. 1997, 272, 2192–2198.
References
(1) Metcalfe, D. D.; Baram, D.; Mekori, Y. A. Mast Cells. Physiol.
Rev. 1997, 77, 1033–1079.
(2) Williams, C. M.; Galli, S. J. The diverse potential effector and
immunoregulatory roles of mast cells in allergic disease. J. Allergy
Clin. Immunol. 2000, 105, 847–859.
(11) Sugo, T.; Tachimoto, H.; Chikatsu, T.; Murakami, Y.; Kikukawa,
Y.; Sato, S.; Kikuchi, K.; Nagi, T.; Harada, M.; Ogi, K.; Ebisawa,
M.; Mori, M. Identification of a lysophosphatidylserine receptor
on mast cells. Biochem. Biophys. Res. Commun. 2006, 341, 1078–
1087.
(12) Dreef-Tromp, C. M.; Lefeber, A. W. M.; van der Marcrel, G. A.;
van Boom, J. H. Synthesis and Phosphorylating Properties of
Hydroxyamino Acid Phosphoramidites. Synthesis 1992, 1992,
1269–1272.
(13) Xu, Y.; Aoki, J.; Shimizu, K.; Umezu-Goto, M.; Hama, K.;
Takanzawa, Y.; Yu, S.; Mills, G. B.; Arai, H.; Qian, L.; Prestwich,
G. D. Structure-Activity Relationships of Fluorinated Lysopho-
sphatidic Acid Analogues. J. Med. Chem. 2005, 48, 3319–3327.
(14) Bruni, A.; Bigon, E.; Battistella, A.; Boarato, E.; Mietto, L.;
Toffano, G. Lysophosphatidylserine as histamine releaser in mice
and rats. Agents Actions 1984, 14, 619–625.
(3) Martin, T. W.; Lagunoff, D. Interactions of lysophospholipids and
mast cells. Nature 1979, 279, 250–252.
(4) Smith, G. A.; Hesketh, T. R.; Plumb, R. W.; Metcalfe, J. C. The
exogenous lipid requirement for histamine release from rat perito-
neal mast cells stimulated by concanavalin A. FEBS Lett. 1979,
105, 58–62.
(5) Horigome, K.; Tamori, Y., N.; Inoue, K.; Nojima, S. Effect of
serine phospholipid structure on the enhancement of concanavalin
A-induced degranulation in rat mast cells. J. Biochem. 1986, 100,
571–579.
(6) Tamori, N. Y.; Horigome, K.; Inoue, K.; Nojima, S. Metabolism of
lysophosphatidylserine, a potentiator of histamine release in rat
mast cells. J. Biochem. 1986, 100, 581–590.
(7) Chang, H. W.; Inoue, K.; Bruni, A.; Boarato, E.; Toffano, G.
Stereoselective effects of lysophosphatidylserine in rodents. Br.
J. Pharmacol. 1988, 93, 647–653.
(8) Hosono, H.; Aoki, J.; Nagai, Y.; Bandoh, K.; Ishida, M.; Taguchi,
R.; Arai, H.; Inoue, K. Phosphatidylserine-specific phospholipase
A1 stimulates histamine release from rat peritoneal mast cells
(15) Shore, P.; Burkhalter, A.; Chon, V. A method for fluometric assay
of hismamine in tissue. J. Pharmacol. Exp. Ther. 1956, 127, 182–
186.